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1 Introduction 
1.1 Preamble 
The presented study was designed to gain insight into the pathophysiology of chronic 
intestinal inflammation as a characteristic of inflammatory bowel disease (IBD) using 
several models of intestinal inflammation. In detail, this study focused on interactions 
of pathophysiological signalling pathways involved in IBD development in preclinical 
model systems. In the following we will address epidemiology, clinical features and 
recent pathophysiological concepts of IBD including fundamental previous studies 
this work is based on.  
1.2 Inflammatory bowel disease 
1.2.1 Clinical features 
Inflammatory bowel disease is a chronic disease characterised by a relapsing-
remitting course of intestinal inflammation. Two main subentities are known: Crohn’s 
disease (CD) and ulcerative colitis (UC). IBD is caused by a multifactorial interplay of 
genetic susceptibility and misbalanced host-microbiota interactions (1). Even though 
CD and UC share several genetic risk factors and have similar epidemiology, they 
differ in anatomical sites of inflammatory activity, macroscopic and microscopic 
appearance of inflamed bowel and degree of inheritance (2). Macroscopically, CD is 
characterised by skipping lesions which can involve the entire gastrointestinal tract 
and transmural inflammation resulting in frequent development of fistulas (2). By 
contrast, UC only affects the colorectum and inflammation is confined to the mucosa 
(2). On microscopic level, non-caseous epithelioid granulomas are typical for CD, 
while crypt abscesses and goblet cell differentiation defects are hallmarks of UC 
histology (2). Both IBD entities are associated with other autoimmune disorders like 
primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC) and other 
extraintestinal manifestations like oligoarthritis or sacroileitis, uveitis, erythema 
nodosum, liver manifestations and psychiatric disorders (2). Moreover, chronic 
inflammation favours oncogenesis, resulting in higher colorectal cancer risk in UC 
and to a smaller extent CD patients (2, 3).  
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1.2.2 Environmental factors 
IBD is a typical multifactorial disease with both inherited and environmental 
contributions to the pathogenesis of the disease. IBD is more prevalent in western 
European or northern American countries. The incidence steeply rises, particularly in 
emerging country like China and India, pointing towards a critical role of high 
socioeconomic levels rather than geographic factors in the aetiology of IBD (4, 5). 
This hypothesis is underscored by findings from migrant studies, which demonstrated 
increased risk of developing IBD (and other multifactorial disorders) for immigrants 
from low prevalence regions moving to countries with higher IBD prevalence (6).  
Smoking has been identified as the most prominent modulator of disease 
development. Active smokers are at higher risk in developing Crohn’s disease in a 
dose-dependent manner while they are paradoxically protected against the 
development of UC (7-9). Nutrition habits have dramatically changed over the last 
century and have hence been implicated in the development of intestinal 
inflammation (10). A high-fat “Western” diet containing high amounts of sugars, fats 
and oils is associated with an increased risk for the development of CD (11), while for 
each single compound both protective and risk associations were found (12). Hence, 
most findings from the dietary studies remain inconclusive and do not point towards 
general protective or deleterious factors. However, Chassaing et al. showed that two 
commonly used food emulsifiers (carboxymethylcellulose and polysorbate-80) in 
manufactured products perturb intestinal microflora and raze the epithelial barrier and 
hence promote intestinal inflammation as well as metabolic disorders (13).  
Indeed, intestinal dysbiosis in IBD patients hinted towards the microbial gut flora as a 
potential mediator of IBD development (14, 15). Usage of antibiotics in early 
childhood disturbs physiological development of a balanced microbial community, 
which is associated with increased vulnerability to the development of IBD (16). While 
most studies fail to pinpoint certain microbes as definite causes of IBD, they revealed 
perturbed composition of the gut bacterial (and viral/fungal) community due to 
dysfunction of a host defence mechanism or environmental factors. Interestingly, a 
study by Lupp et al. demonstrates colonic microbial changes in inflamed intestines 
irrespective to the trigger – be it in response to chemical triggers, genetic 
predispositions or infectious agents (17). This study fuels the current discussions on 
the disturbed microenvironment as a result or bystander of intestinal inflammation, 
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leading to a yet unsolved “hen and egg”-problem. Strategies to cure IBD by restoring 
“healthy” gut microbial communities, e.g. via faecal microbial transfer (FMT), have 
very ambiguous outcomes at the current stage (18); at best, a non-stable induction of 
remission can be achieved by intensive FMT (19).  
In sum, environmental components potentially influence disease development and 
outcome as risk factors, however it is difficult (and currently impossible) to pinpoint 
down a specific trigger in an affected individual.  
1.2.3 Genetic factors 
A myriad of studies linked genetic factors to disease development. Using novel 
genome sequencing methods, large-scale genetic studies identified over 200 single-
nucleotide polymorphisms (SNPs) which confer increased risk for the development of 
IBD (20). Moreover, some IBD risk genes have been associated with other 
autoimmune disorders like primary sclerosing cholangitis (21), asthma bronchiale and 
type I diabetes and susceptibility to mycobacterial infections (22), pointing at least 
partly to a unifying immunological principle which is disturbed in the development of 
chronic inflammatory disease.  
The most well known risk genes associated with high risk for Crohn’s disease are 
nucleotide-binding oligomerization domain-containing protein 2 (NOD2) (23), coding 
for a pathogen-associated molecular pattern (PAMP)-recognising receptor, and 
autophagy-related protein 16-1 (ATG16L1), a critical scaffold protein involved in 
autophagy (24). Many of these genes found can be categorised in genes involved in 
innate immune regulation and maintenance of barrier integrity. These genes can also 
be functionally clustered e.g. to cytokine signalling (e.g. IL23R, JAK2, TYK2, IL7R), 
autophagy (e.g. ATG16L1, IRGM, LRRK2) and endoplasmic reticulum (ER) stress 
related genes (e.g. ORMDL3, XBP1). Indeed, the genetic landscape reveals a strong 
contribution of epithelial signals in IBD pathophysiology. While IBD was initially 
regarded as a primarily immune cell driven disorder (25), the concept of epithelial 
dysfunction has emerged as a major regulator in disease development. In particular, 
barrier-enhancing cytokines, epithelial ER stress and autophagy were some of the 
most intensely investigated mechanistic processes, which are highlighted in the 
following chapters. 
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Familial observation studies revealed the impact of inheritance on IBD with the 
highest individual risk for IBD development in first-degree relatives of  IBD patients 
(26). In these constellations, a high concordance rate (70.1-83.8%) in disease type, 
extent and extraintestinal manifestations can be observed (27). In twin studies 
including monozygotic twins, high concordance rates in CD (around 25%) were 
observed, with a smaller extent in UC (28, 29), thus underscoring the impact of the 
genetic architecture to the genesis of IBD.  
A very small proportion of IBD has been described to be mono- or oligogenic 
diseases with mutations e.g. in genes encoding for X-linked inhibitor of apoptosis 
protein (XIAP) (30), interleukin-10 (IL10) (31) or interleukin-10 receptor (IL10R) (32) 
as underlying causes. These monogenic IBD syndromes generally have very early 
onset (< 6 years of age) with a more severe, complicated and therapy-refractory 
disease course (33). Despite a small number of patients suffering from 
mono/oligogenic IBD syndromes, these cases are potentially treatable by targeted 
therapeutic approaches calling for in-depth functional studies of the underlying 
biology. For instance, abatacept treatment in cytotoxic T-lymphocyte-associated 
protein 4 (CTLA4)-mutated patients has shown efficacy in case series (34). However, 
most IBD cases are considered as non-Mendelian polygenic disorders, thus 
complicating genetic risk estimates and calling for more complex therapeutic 
approaches.  
1.2.4 Current therapeutic approaches 
Due to the complexity of IBD pathophysiology no causal therapy has been 
successfully developed yet. Current therapeutic strategies involve rather unspecific 
immunosuppression and targeted antagonism of inflammatory cytokines to restrain 
but not cure inflammation (35).  
Mesalazine (or 5-aminosalicylic acid), an anti-inflammatory aminosalicylate, and 
budesonide, a topically effective corticosteroid without systemic effects, are first-line 
therapeutics in IBD and can be given orally or as an enema for lower bowel 
conditions (36). In case of stronger disease activity, systemic corticosteroids, 
azathioprine, methotrexate and 6-mercaptopurine are commonly used 
immunosuppressive drugs to induce and maintain remission (37). Relevant adverse 
events include unspecific immunosuppression leading to increased vulnerability to 
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infections (38), along with toxicity of the drugs (e.g. myelosuppression) (37) and 
stigmatising Cushing’s syndrome, which includes diabetes, abdominal obesity, high 
blood pressure and round red face (39).  
In severe IBD cases, therapeutic recombinant antibodies targeting specific immune 
pathways (e.g. TNFα, IL-23) are the current mainstay in the treatment of IBD. 
Although they are more expensive drugs than conventional immunosuppression, their 
usage leads to reduced healthcare costs due to reduced hospitalization and surgery 
(40). Prototypically, blocking of tumor necrosis factor alpha (TNFα), one of the key 
inflammatory cytokines in inflammatory diseases, has been shown to be effective in 
IBD treatment (41), therefore anti-TNFα antibodies like infliximab, adalimumab, 
certolizumab pegol and golimumab are included in induction and maintenance 
therapy schemes (42-44). In the following, other mechanistic targets have been 
identified in IBD therapy: Vedolizumab, a recombinant antibody against α4β7-
integrin, blocks immune cell infiltration from gut vessels and is effective as an 
escalation therapy (45). Ustekinumab (anti-IL12/IL-23 antibody) has been approved 
for IBD therapy which targets the p40 subunit shared by IL-12 and IL-23 (46). Very 
recently, tofacitinib (small molecule Just Another Kinase (JAK) inhibitor) (47) has 
been approved by the FDA for UC treatment since June 2018. Further promising 
drugs which are under development are etrolizumab (anti-αEβ7-integrin antibody) 
(48) and ozanimod (RPC-1063, sphingosine-1-phosphate receptor agonist) (49).  
1.3 The role of IL-22 in intestinal inflammation 
IL-22 is a cytokine of the IL-10 superfamily first described in 2000 (50). Due to 
structural similarity to IL-10, IL-22 deploys its function via binding the transmembrane 
receptor complex consisting of the subunits IL-22R1, which is also shared by IL-20 
and IL-24 from the same cytokine family, and IL-10R2 (50). IL-22 is a tissue-
protective cytokine in intestinal mucosal immunity, but has also been implicated to 
play a role in psoriasis (51), hepatitis (52), pancreatitis (53), chronic lung (54) and 
joint inflammation (55). The main effects of IL-22 are assigned to its downstream 
activation of intracellular JAK-signal transducer and activator of transcription (STAT) 
signalling, particularly STAT3 (56). Main physiological consequences of IL-22-
dependent STAT3 activation in intestinal epithelial cells are related to antimicrobial 
peptide (57) expression, promotion of epithelial regeneration (56) and 
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posttranslational modification of secreted proteins (58). Indeed, IL-22 was found to 
be the strongest inducer of STAT3 in the intestinal epithelium, thus IL-22 is regarded 
as the strongest tissue protective cytokine in intestinal inflammation (56). As such, IL-
22 is regarded as the archetypical barrier protective cytokine, which bears high 
potential for therapeutic exploitation in immune-related diseases, e.g. IBD (59) and 
graft versus host disease (GvHD) (60). STAT1 and STAT5 activation upon IL-22 
stimulus is weaker than STAT3 activation (61), however evidence pointing towards 
an important role of STAT1 in IL-22 signalling has been put forward. Type I 
interferons like interferon (IFN)α and IFNβ synergistically enhance IL-22-dependent 
STAT1 signalling and thus potentiate the pro-inflammatory properties of IL-22 in the 
intestine (60, 62). Additionally, activation of the mitogen-activated protein kinase 
(MAPK) pathways and the phosphoinositide 3-kinase (PI3K)-Akt-mechanistic target 
of rapamycin (mTOR) pathway may also play important roles in IL-22 downstream 
signalling (61, 63).  
While epithelial cells of barrier organs (e.g. skin, lung, intestine) are the primary 
receiver of IL-22 signals, IL-22 is secreted from a plethora of immune cells circulating 
in the underlying mucosal tissue. Hence, IL-22 is one of only a few unidirectional 
cytokine bridging immune cell signals with epithelial functions. In detail, IL-22 has 
been shown to produced by T cells, in particular T helper 1 (Th1), Th17 (64, 65), Th22 
(66, 67), CD8+ T cells,  natural killer T (NKT) and γδT cells (68). Other cellular 
sources are neutrophilic polymorph nuclear (PMN) cells (69) and innate lymphoid 
cells (ILCs) like NK cells, lymphoid tissue inducer (LTi) cells, and natural cytotoxicity 
triggering receptor (NCR)+  ILCs (70, 71) .  
Expression of IL-22 is controlled by several mechanisms. While the aryl hydrocarbon 
receptor (AhR) is a transcriptional regulator of IL22 expression (72, 73), pro-
inflammatory cytokines like IL-17, IL-12, IL-23 and IL-6 (64) promote IL-22-dependent 
effects. In particular, IL-23 licenses production of IL-22 through binding to its receptor 
IL-23R on dendritic cells (74). Our working group demonstrated that intestinal 
epithelial cell (IEC)-specific expression of Il23r also orchestrates IL-22 production in 
the intestinal mucosa in a murine model, underpinning the complexity of regulatory 
crosstalks between various cell types in gut inflammation (75). Intriguingly, loss of 
Il23r in IECs diminished inducible IL-22 levels in the intestinal mucosa, resulting in a 
severe experimental colitis due to the insufficiency of IL-22-dependent protective 
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signals (75). In general, IL-22 is highly expressed in inflammatory conditions, e.g. IBD 
or rheumatoid arthritis (55). Higher numbers of IL-22 producing cells in intestinal 
mucosa of IBD patients (76) can be found, but also systemically elevated levels of IL-
22 are positively correlated with disease activity (77). Mice lacking Il22 expression 
succumb in an experimental colitis model using dextrane sodium sulphate (DSS), 
hereby demonstrating the regenerative impact of IL-22 in intestinal inflammation (78). 
However, IL-22 and its downstream effects seem to be tightly regulated by a natural 
antagonist called IL-22 binding protein (IL-22BP), which is a soluble single-chain IL-
22R not encoded by IL22R1 (79) and expressed in several tissues including the 
intestinal mucosa. In an acute inflammatory state, IL-22BP is down-regulated (78), 
presumably to disinhibit tissue-protective IL-22 effects. On the contrary, a 
carcinogenesis promoting role of IL-22 due to increased epithelial proliferation and 
inhibition of cellular differentiation has been described in the gut (78), liver (80) and 
connective tissue (81). Thus, the role of IL-22 in the context of intestinal inflammation 
seems to be ambiguous. Despite these findings, efforts are made to establish IL-22 
or IL-22-dependent signalling as therapeutic targets in IBD treatment. IL-22Fc 
(UTTR1147A) is a recombinant fusion protein of IL-22 with the Fc part of human 
immunoglobulin (Ig) G4 antibodies which passed pre-clinical safety and 
pharmacological studies in mice, rats and cynomolgus monkeys (59). Currently, a 
phase Ib study with intravenous UTTR1147A in healthy volunteers and volunteering 
patients with UC and CD is evaluating safety of this therapy (ClinicalTrials.gov 
identifier: NCT02749630).  
1.4 The intestinal epithelium – a multitalented barrier 
The intestinal epithelium is a monolayer containing a variety of specialised cells, 
which (in a homeostatic state) meet the demands of both proper nutritional function 
and sufficient protection against luminal harmful stimuli, e.g. invading microbes (82). 
Most of the defence mechanisms originate from the epithelial cells either by providing 
a physical barrier, cell intrinsic strategies or secreted components for host protection 
(figure 1-1). While the epithelial architecture varies along the whole gastrointestinal 
tract (82) I will  focus on the small and large intestine as these are the main sites of 
IBD activity (2) and point out the unifying principles of epithelial biology that are 
present at all sites of the intestine. The secretory defence line, mainly consisting of 
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mucins (83), immunoglobulins and antimicrobial peptides (AMP) (75, 84-86) is 
important as physical and immunological host barrier in antimicrobial defence. 
However, as it would be beyond the scope, I did not address their interesting role in 
intestinal inflammation in this thesis work. 
 
 
Figure 1-1: Main defence strategies of the intestinal epithelial barrier 
(a) IECs and their innate defence mechanisms like autophagy, (b) tight junctions, (c) the 
mucus layer and (d) antimicrobial peptides contribute to the barrier function of the intestinal 
epithelium. 
1.4.1 Epithelial integrity as a stronghold of host-defence against 
pathogens 
The small intestinal epithelium is spread along the crypt-villus axis. In the villus part, 
mainly enterocytes and goblet cells with interspersing M-cells and enteroendocrine 
cells are located, whereas the crypt fraction also harbours Paneth cells, intestinal 
stem cells (ISC) and the highly proliferative transit-amplifying cell zone (TAC) (82). 
Immune cells are in close communication with the epithelium; some even reside in 
the barrier itself, so-called intraepithelial lymphocytes (87). In contrast, the colonic 
epithelium forms no villi but only crypts, containing more goblet cells but otherwise 
similar distribution of epithelial cell types and a functionally similar subset of cells in 
the crypt bottom as in the small intestine (82).  
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Specialised cellular contacts including tight junctions, adhering junctions and 
desmosomes, are essential for the integrity of epithelial tissues as well (82). IBD 
patients displayed lower expression of tight junction proteins like occludin and ZO-1, 
causing an increased gut permeability, which may contribute to intestinal 
inflammation (88, 89).   
1.4.2 Cell death & regeneration: Cellular fate towards harmful 
stimuli 
Harmful stimuli like irradiation, pathogens, chemicals, humoral signal or nutritional 
deprivation lead to cellular stresses like oxidative stress and ER stress. If the cellular 
damage is irreversible, cellular fate is skewed towards cell death. Defects of the 
epithelial layer, e.g. by cellular death or by tissue wounding leads to a defective 
physical and immunological barrier function and thus favour an inflammatory 
phenotype of the intestine (90). In particular, epithelial cell death is a hallmark of 
intestinal inflammation and has therefore extensively been studied. For instance, 
TNFα is a key pro-inflammatory cytokine in IBD which can induce an immunogenic 
type of epithelial cell death called necroptosis besides classic apoptosis in murine 
models and in CD patients (91). Necroptosis is a programmed cell death modality 
characterised by cellular lysis and efflux of intracellular contents without blebbing and 
is therefore distinct to caspase-mediated apoptosis. Genetic deletion of epithelial 
caspase-8, one of the critical regulators of apoptosis, led to necroptotic cell death 
upon TNFα and subsequent spontaneous ileitis and high susceptibility to 
experimental colitis (91). Other inflammatory cytokines (like interferon gamma (IFNγ) 
(92)) and cellular stress signals can contribute to death of epithelial cells, e.g. 
uncontrolled ER stress (93), autophagy defects (94) and excessive inflammasome 
activation (95). 
Epithelial regeneration is an adaptive proliferative response toward tissue damage 
aiming to minimize the epithelial barrier defects and re-establish containment of 
potential harmful stimuli within the intestinal lumen. Epithelial regeneration exploits 
the molecular principles of cellular proliferation by orchestrating simultaneous 
proliferation and differentiation on an epithelial cell type specific level (e.g. stem cells, 
transit amplifying cells, goblet cells, Paneth cells). The crypt bottom, which forms a 
niche for stem cell, is crucial for epithelial regeneration: Intestinal stem cells (ISC) are 
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the stem cell pool for all epithelial cell types, and their function is critically dependent 
on the interspersed Paneth cells (96). Stem cell proliferation is dependent on 
canonical Wnt and STAT3 signalling (97, 98).  
Importantly, interleukin (IL)-22 (which activates STAT3) promote epithelial 
regeneration by boosting the function and protection of the stem cell niche (60, 98). 
Vice versa deletion of STAT3 in the intestinal epithelium (Stat3ΔIEC mice) attenuates 
regenerative capacity, ultimately leading to defective wound healing in an 
inflammatory setting and thus perpetuating disease (56). As described before, these 
tissue protective properties of IL-22 gave rise to the rationale of designing 
recombinant IL-22-based treatments (59). This outstanding role of IL-22 in 
proliferation is underscored by increased tumorigenesis in the intestine (78) and the 
biology of psoriasis, another inflammatory disorder of the skin: Here, IL-22 is the 
driving force of keratinocyte hyperproliferation and hence IL-22 inhibition is under 
evaluation as a novel therapy concept (99).   
In this context, Leucine-rich repeat -containing G-protein coupled receptor 5 (LGR5) 
is a marker surface receptor implicated in Wnt signalling and mainly expressed in ISC 
(100). The natural ligand of LGR5 is R-Spondin1, which was shown to boost Wnt-
signalling in synergy with Wnt3a (101). However, the definite cellular source of R-
Spondin1 remains to be investigated. Transforming growth factor beta (TGFβ) 
signalling is another critical stimulatory axis for stem cell function  (102). Bone 
morphogenetic protein 4 (BMP4), a member of the TGFβ superfamily and exclusively 
expressed in the intravillus mesenchyme, repressed de novo crypt formation (102). 
Transgenic overexpression of the antagonist noggin led to overt proliferation and de 
novo crypt generation in a mouse model (102). Epidermal growth factor (EGF) was 
shown to drive intestinal epithelial proliferation as well (103).  
Moreover, the Hippo-Yes-associated protein (YAP) pathway has been implicated in 
stemness and regeneration (104). By contrast, TAC are the most proliferative cell 
type amongst the intestinal epithelial cells (IEC) and contribute to rapid epithelial 
turnover (82). ISC and TAC function are linked in an mTORC1-dependent fashion 
(96). Whereas homeostatic epithelial proliferation under physiological conditions is 
mainly driven by cell intrinsic signalling programs epithelial wound healing greatly 
depends on exogenous regenerative stimuli secreted from residing cells in the 
intestinal mucosa.  
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The knowledge of the underlying molecular event of stem cell proliferation has 
empowered Sato et al. to implement in vitro three-dimensional epithelial culture 
models, which are referred as intestinal organoids (105). After isolation of the stem 
cell niche, they were embedded into a gel-like collagen matrix and stimulated with 
epidermal growth factor (EGF), R-spondin1 and noggin, which essentially maintain 
intestinal stemness by activating the EGF receptor (EGFR) and Wnt pathways and 
suppressing transforming growth factor-beta (TGFβ) signalling, respectively. As a 
consequence, stem cells autonomously divide and their offspring form crypt-like 
structures with clear polarization and differentiate into all known intestinal epithelial 
cell types. This technology has been transferred to other tissues like hepatic (106) 
and even neuronal tissues (107). Also, human organoids are effectively investigated 
(108). Organoids represent an adequate model for studying intestinal epithelial 
biology and have been used for biomedical purposes like drug screenings, bio-
banking (109), transplantation (110) etc. As exemplified in this work, intestinal 
organoids are increasingly often used to study the epithelial biology.  
 12 
 
Figure 1-2: Conception of intestinal organoid cultures 
(a) Scheme of small intestinal epithelium architecture. Crypts provide the stem cell niche, 
were Paneth cells and different stem cell subsets like Lgr5+ +5 cells and crypt base columnar 
cells reside. Next to the crypt base transit amplifying (TA) cells can be found, which serve for 
massive tissue renewal at baseline conditions. (b) Isolated crypts were embedded into a 
collagen matrix, which is then overlaid by stem cell medium containing EGF, noggin and R-
spondin1. (c) Crypts develop cystic formations after one day in culture, providing cellular 
luminal-basolateral polarity. (d) Evolved crypt-derived organoids with multiple crypt-like stem 
cell niches and villus-like epithelium. (e) Freshly isolated epithelial crypts in suspension. (f), 
(g) Corresponding microscopic captures to (c) and (d). 
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1.4.3 Innate strategies to cope with microbial invasion 
Intestinal epithelial cells have intrinsic strategies to react to microbial pathogen 
invasion. Both intra- and extracellular pattern recognition receptors like Toll-like 
receptors (TLRs), NOD and NOD-like receptors, cyclic GMP-AMP synthase (cGAS) 
etc. mediate anti-infective response upon sensing of microbial molecules (111). In 
addition, these receptors serve as adaptors or scaffolds for effector mechanisms in 
intestinal epithelial cells like autophagy induction and generation of reactive oxygen 
species (ROS) (111). In brief, the induction of bactericidal ROS like hydrogen 
peroxide (H2O2) or superoxide (O2-) have been implicated in host defence against 
intracellular pathogens (112). Recently, our working group has shown that NOD2-
dependent ROS generation, in particular of O2-, is crucial for antibacterial defence 
(113). 
Cytosolic DNA is a danger signal for either massive DNA damage with extrusion of 
DNA fragments from the nucleus to the cytoplasm (114) or for the presence of 
intracellular microbes (115). Several receptors sense microbial nucleic acid, e.g. 
TLR9 (116), absent in melanoma 2 (AIM2) (117), cGAS (118) and retinoic acid 
inducible gene (RIG)-I (119). cGAS detects double stranded (ds)DNA to produce the 
second messenger cyclic guanosine monophosphate-adenosine monophosphate 
(cGAMP). cGAMP in turn can also be produced by viable intracellular bacteria and is 
sensed by the ER-resident stimulator of interferon genes (STING), which leads to 
phosphorylation of TANK-binding kinase 1 (TBK1) and thus ultimately mediate a 
type-I interferon signal to counteract microbial infections (120). STING signalling has 
been implicated in inflammatory diseases (115) and cancer biology (121) and is 
hence extensively studied. In particular, the idea of an intrinsic sensing of harmful 
signals like dsDNA (be it through release of damaged DNA from the 
cytosol/mitochondrion or through external stimulation like viral infection) which 
induces a strong inflammatory program is focussed in recent work as therapeutic 
target (122). Concurring with this, RIG-I senses cytosolic (viral) ss/dsRNA to activate 
downstream melanoma differentiation antigen (MDA)5 and mitochondrial antiviral-
signaling protein (MAVS) to ultimately induce IFN-I production (119). 
Another potent mechanism limiting microbial propagation across the epithelium is the 
induction of autophagy and xenophagy of intracellular pathogens (123). Intriguingly, 
NOD2 recruits ATG16L1 to the plasma membrane for induction of xenophagy, 
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suggesting requirement of physical protein-protein interaction for proper ATG16L1-
dependent xenophagy (124). The role of autophagy in IBD and the composition of 
the related ER stress machinery will be detailed in chapter 1.5.  
1.5 Autophagy and ER stress resolution – critical 
mechanisms in epithelial homeostasis  
1.5.1 ER stress 
The endoplasmic reticulum (ER) is the cellular organelle required for synthesis and 
primary post-translational processing (e.g. N-linked glycosylation and disulphide bond 
formation) of nascent secretory and transmembrane proteins. It forms a reticular 
plexus communicating with the outer lipid bilayer of the nuclear membrane (125). 
Accumulation of un-/misfolded proteins, e.g. in a state of high secretory activity, leads 
to their aggregation in the ER and subsequent cellular stress called ER stress, which 
can direct cellular fate towards cell death (125). To control excessive ER stress and 
to avoid severe tissue damage due to cellular malfunction, evolutionary highly 
conserved signalling pathways, summarised as the unfolded protein response (UPR), 
guard either re-establishment of cellular homeostasis or serve as checkpoint for 
programmed cell death if excessive ER stress cannot be resolved (125). Considering 
this, it is not surprising that highly secretory cells (like Paneth cells) are the most 
vulnerable cell types to ER stress and have the strongest UPR activation within 
tissues (93).  
The folding capacity of the ER can be modulated by several intrinsic and extrinsic 
factors like hypoxia (126), ROS (127), saturated fatty-acids (128) pathogens (129) 
and ageing (130). A particular role of the ER has been pinpointed in the context of 
viral infections as replicating viruses perturb ER function for production of viral 
proteins (131). Other pathogens selectively modulate distinct UPR pathways to 
ensure their survival (132). ER stress can be experimentally induced e.g. by 
tunicamycin (inhibition of N-glycosylation) or thapsigargin (calcium efflux from the 
ER) (133). 
Mechanistically, three ER resident transmembrane proteins integrate UPR activity: 
inositol-requiring enzyme 1α (IRE1α, ERN1), PKR-like ER kinase (PERK, EIF2AK3) 
and activating transcription factor 6 (ATF6) (125). Binding immunoglobulin protein 
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(BiP, GRP78, HSPA5), a chaperone, represses the activity of these three ER stress 
sensors in a compensatory state, but associates with misfolded proteins under ER 
stress conditions and which ultimately lead to disinhibition of the UPR (134) (see 
figure 1-3).  
One important regulator of ER stress, XBP1, has been identified as an important IBD 
risk factor (93). Under ER stress conditions, IRE1α, an endonuclease, splices XBP1 
to generate the spliced XBP1 (XBP1s) form which after translation acts as a 
protective transcriptional factor for chaperones and other ER-resident proteins (135). 
Vice versa XBP1 negatively regulates IRE1, thus propagating pro-inflammatory 
signalling and cell death e.g. via JNK (136) and development of colitis-associated 
carcinogenesis (93, 137). Besides splicing of XBP1, activated IRE1 cleaves aberrant 
mRNA with its endonuclease domain which is called regulated IRE1-dependnet 
decay (RIDD). Together with p-eIF2α, a downstream regulator of PERK, cleaved 
mRNA fragments after RIDD prevent further accumulation of misfolded proteins (138, 
139). Moreover, ER stress impairs epithelial regeneration by suppressing stem cell 
markers and proliferative activity, another hallmark of intestinal inflammation (140).  
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Figure 1-3: Conception of the unfolded protein response (modified from (125) with 
permission from Springer Nature) 
Three ER-resident transmembrane proteins propagate critical stress signals upon 
accumulation of misfolded proteins in the ER: BiP recognises and binds to misfolded proteins 
dissociating from IRE1, PERK and ATF6, thereby disinhibiting their downstream signals, 
culminating in binding of the transcription factors XBP1s, ATF4 and cleaved ATF6 to target 
genes encoding for cell-protective mechanism like chaperones or cell death induction (e.g. 
CHOP (141)). In parallel, regulated IRE-dependent decay (RIDD) of mRNA and p-eIF2α 
downstream of pPERK lead to translational arrest/attenuation.  
1.5.2 Autophagy 
Autophagy is a “cannibalistic” mechanism serving to cope with stressful condition 
(e.g. starvation) due to the orderly degradation of subcellular components and 
pathogens. It serves various purposes in housekeeping cellular function, for instance 
recycling of unused and senescent cellular components in a state of starvation (142). 
Three different autophagy types are described (see figure 1-4): The classic mode 
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termed as macro-autophagy serves degradation of cytoplasmic cargo enveloped in a 
double membrane-bound vesicle called autophagosome via fusion with lysosome, 
referred to as autolysosome (142). However, micro-autophagy describes a process in 
which cytosolic components are directly engulfed by lysosomes (142). Finally, 
translocation of proteins complexed with chaperone proteins (e.g. Hsc70) via 
lysosomal-associated membrane protein 2A (LAMP-2A) across the lysosomal 
membrane has been referred to as chaperone-mediated autophagy (143). Most 
recent work focuses on the role of macro-autophagy, which therefore is hereinafter 
referred to as “autophagy”.  
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Figure 1-4: Conception of the main types of autophagy (modified from (143) with 
permission from Springer Nature) 
Three main subtypes of autophagy are depicted in this graphic: Nascent isolation 
membranes, consisting of phospholipid bilayer double membranes, engulf dispensable 
organelles, proteins and pathogens, finally isolating them in autophagosomes. Fusion with 
lysosomes results in degradation of the isolated structures, a process called 
macroautophagy. Small amounts of these organelles or proteins can be directly taken up by 
lysosomes through endocytosis (microautophagy). Certain substrates can be translocated 
into lysosomes for degradation through specific transporters and chaperones (chaperone-
mediated autophagy).  
Macroautophagy is targeted towards certain aged organelle structures e.g. 
mitochondria (then referred to as mitophagy) (144), ER membrane (ER-
phagy/reticulophagy) (145) or pathogens (xenophagy) (123). Impaired mitophagy has 
been associated with degenerative diseases like Parkinson’s disease, suggesting a 
role of dysfunctional removal of cellular compartments in the aetiology of human 
disease (146). Selective autophagy requires specific adaptor molecules for the 
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autophagosomes to target specific sites. Optineurin has been linked to ER-phagy 
(130, 147) and mitophagy (148) in context of both neurodegeneration und 
inflammatory diseases like IBD. Interestingly, also protein complexes can be 
targeted, as exemplified by the role of the tripartite motif (TRIM) family in targeting 
regulatory elements of the innate immunity like NLRP3 (inflammasome formation) or 
IRF3 (type I interferon response) (149) (150). Autophagy is controlled by different 
pathways, including Beclin-1 (151) and mTOR (152).  
Defective autophagy has been associated with many inflammatory and degenerative 
conditions like IBD. Autophagy-related 16-like 1 (ATG16L1) is a pivotal autophagy 
regulator, with the T300A variant conferring risk for the development of CD (24). 
ATG16L1 is required for the assembly of various autophagy-related gene (ATG) 
products like ATG5, ATG7, ATG10 and ATG12 to form a complex essential for 
autophagosome formation. The ATG16L1T300A (refseq number: rs2241880) variant 
can be cleaved by caspase 3, leading to loss of protein function (153). In ER stress 
conditions, Paneth cells are susceptible to impaired autophagy within epithelial tissue 
as shown by loss of functional lysozyme+ granules in IEC-specific knockout of 
Atg16l1 in mice (154). Both loss of Atg16l1 and knock-in of human ATG16L1T300A 
variants resulted in decreased stemness in the intestine and diminished regenerative 
capacity (153). Interestingly, a recent study linked Atg16l1 deficiency with 
immunogenic necroptotic cell death in the context of viral infections, providing 
another mechanistic explanation for ATG16L1 genotype-dependent disease 
susceptibility (94). ATG16L1 has also been implicated as an immune nexus as 
deficient Atg16l1 in immune cells like bone marrow derived macrophages or dendritic 
cells unchained inflammatory processes like inflammasome and NF-κB activation 
(153). Other confirmed autophagy-related risk genes are for instance immunity-
related GTPase family M protein (IRGM) (155) and leucine-rich repeat kinase 2 
(LRRK2) (156) which, however, are less intense investigated.  
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1.5.3 The interplay of autophagy and ER stress in intestinal 
inflammation 
Autophagy and UPR are not isolated processes, but indeed have molecular 
interdependencies on many levels. UPR induces autophagy via the PERK-eIF2α 
signalling branches (and the downstream factors activating transcription factor 4 
(ATF4) and C/EBP homologous protein (CHOP)) (157) and IRE1α activation (158). In 
addition, UPR pathways can restrain mTOR activity via AMP kinases (AMPK) to 
induce autophagy (159).  
Autophagy induction acts as compensatory machinery in order to repress overt ER 
stress and subsequent UPR activation. In the scenario of intestinal inflammation, 
epithelial ER stress as in Xbp1ΔIEC mice induces autophagy in an eIF2α-dependent 
fashion which in turn controls IRE1α activity (see figure 1-5). Concomitant knockout 
of Atg16l1 or Atg7 ultimately disinhibits UPR activity, resulting in spontaneous 
excessive cellular death and severe transmural ileitis in young adult 
Atg16l1ΔIEC/Xbp1ΔIEC mice, reminiscent of the classic CD phenotype (160). The 
aforementioned Paneth cell disorder might be causative for this phenomenon as mice 
harbouring a Paneth cell-specific deletion of Xbp1 have a similar phenotype. Also, 
aged Atg16l1ΔIEC mice phenocopied Atg16l1ΔIEC/Xbp1ΔIEC mice, presumable due to 
chronic accumulating ER stress associated with age (130). In line with these murine 
in vivo data, Deuring et al. demonstrated high expression levels of ER stress markers 
like GRP78 and p-eIF2α in Paneth cells of CD patients harbouring ATG16L1T300A 
variants correlate with more fistula and need for intestinal surgery (161). However, 
the detailed mechanism by which autophagy controls ER stress are not fully 
understood.  
Cytokines regulate and modify ER stress. A recent study demonstrated the role of IL-
10 in attenuating experimental colitis via suppression of epithelial ER stress (162). 
The same working group showed that IL-22 ameliorates ER stress in ß cells (163). 
These findings point towards an ER stress-modulating role of cytokines of the IL-10 
family, in particular of the protective cytokine IL-22. IL-22 has also been implicated in 
autophagy regulation and depending on cellular context, can suppress and promote 
autophagy (164, 165). In this study, I dissected the role of IL-22 in autophagy and ER 
stress regulation in a preclinical model of intestinal inflammation. 
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Figure 1-5: Interplay of autophagy and ER stress in the intestinal epithelium (modified 
from (125) with permission from Springer Nature) 
(a) Intestinal epithelial cells display physiological UPR in order to maintain ER homeostasis 
while producing secretory proteins. (b) Genetic distortion of critical nexus of the UPR like 
deletion of Xbp1 destabilises the homeostasis towards ER stress, resulting in a NF-κB/JNK-
dependent inflammatory phenotype. Autophagy activation downstream of the PERK branch 
restrains ER stress as a compensatory mechanism. (c) Additional disruption of essential 
autophagy components like Atg16l1 disinhibited ER stress, ultimately leading to caspase 3-
mediated cell death and severe (transmural) intestinal inflammation. 
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2 Aim of the study 
The aim of the following was to study the impact of two fundamental cellular 
homeostatic principles, namely UPR and autophagy, on the fine tuning of cytokine 
induced epithelial proliferation. The following preliminary data from other studies gave 
rise to the design of the hypothesis:  
- Epithelial ER stress and defective autophagy are associated with impaired 
regeneration of the epithelial barrier. 
- IL-22 promotes epithelial proliferation via activation of JAK/STAT pathway 
- IL-10, a cytokine structurally related to IL-22, has been shown to promote 
epithelial regeneration via mechanism involving the alleviation of epithelial ER 
stress.  
Based on these findings we postulated that pro-regenerative effects of IL-22 are 
mediated via alleviation of epithelial ER-Stress in a STAT1/STAT3-dependent 
manner. In particular, I addressed the following key questions: 
- Does experimental ER stress and autophagy inhibition interfere with the 
regenerative function of IL-22? 
- Does IL-22 vice versa modulate epithelial ER stress or autophagy? 
- Do IL-22 effects differ in vitro and in vivo in the context of genetically 
determined epithelial ER stress or autophagy defects? 
- If yes, what are the molecular switches in intestinal epithelial cells proficient vs. 
deficient for Atg16l1 and Xbp1? 
For this purpose, three different experimental models were employed in this study: 
Human colon carcinoma cell lines for in vitro studies, primary intestinal organoids (as 
a novel ex vivo model for intestinal epithelial tissue) and genetically modified mice to 
study in vivo effects of IL-22.  
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3 Materials & Methods 
3.1 Material  
All materials used are listed in the appendix. Antibodies and primers are listed in the 
appropriate methodological chapters. 
3.2 Methods 
3.2.1 Animals 
Il23rfl/fl;VillinCre (Il23rΔIEC), Atg16l1fl/fl;VillinCre (Atg16l1ΔIEC), Xbp1fl/fl;VillinCre 
(Xbp1ΔIEC) and Atg16l1fl/fl;Xbp1fl/fl;VillinCre (Atg16l1ΔIEC/Xbp1ΔIEC) mice have been 
described previously (75, 93, 160). In brief, Il23rfl/fl (Il23rfl) mice were generated by 
targeted insertion of LoxP sites flanking the exon 4 of the Il23r gene (Genoway, Lyon, 
France). Atg16l1fl/fl (Atg16l1fl) mice were generated by insertion of LoxP sites flanking 
the exon 1 of the Atg16l1 gene (Genoway, Lyon, France). Xbp1fl/fl (Xbp1fl) mice were 
generated by targeted insertion of LoxP sites flanking the exon 2 of the Xbp1 gene. 
VillinCre animals (strain: B6.SJL-Tg(Vil-cre)997Gum/J) were purchased from 
Jackson Laboratory. Conditional knockout of Atg16l1 and Xbp1 in the intestinal 
epithelium was established by crossing VillinCre mice with Atg16l1fl or Xbp1fl mice, 
resulting in specific deletion of Atg16l1 (Atg16l1ΔIEC) and Xbp1 (Xbp1ΔIEC) in the 
intestinal epithelium. Atg16l1;Xbp1;VillinCre double knockout mice were created by 
crossing Atg16l1fl mice with Xbp1ΔIEC. Transgenic WD40-truncated Atg16l1 
(Atg16l1ΔWD40) mice were generated in collaboration with Genoway (166). In brief, a 
Stop-polyadenylation signal cassette was inserted into the exon 10 of Atg16l1, 
leading to ubiquitous expression of truncated Atg16l1 mRNA missing the C-terminal 
region encoding for the WD40-repeat domain. 
Mice harbouring a missense mutation in exon 6 of Tmem173 (Tmem173gt), resulting 
in an isoleucine-to-asparagine change in amino acid 199(167), and Mda5 knockout 
(Mda5-/-) mice were raised at the University Hospital Bonn and kindly provided by 
Gunter Hartmann (Bonn University) for organoid experiments. Intestinal organoids 
derived from Ripk3-/- and Ripk1D138N mice were created in Cologne, cryo-preserved 
and kindly provided by Manolis Pasparakis (University Hospital of Cologne) for 
further experiments. Mlkl-/- mice were raised at Kiel University and kindly provided by 
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Stefan Krautwald (Department of Nephrology, University Hospital Schleswig-Holstein, 
Campus Kiel). 
Genotyping strategies for each transgenic mice strain have previously been 
established and were carried out as described before(93, 119, 160, 166-169). 
All mice were provided with food and water ad libitum and maintained in a 12-h light-
dark cycle under standard conditions (21°C ± 2°C with 60 % ± 5 % humidity) at Kiel 
University (Il23rΔIEC, Xbp1ΔIEC, Atg161ΔIEC, Atg16l1ΔWD40, Mlkl-/-), the University of 
Cambridge (Xbp1ΔIEC/Atg16l1ΔIEC), the University Hospital Bonn (Tmem173gt, Mda5-/-) 
and the University of Cologne (Ripk3-/-, Ripk1D138N).  
3.2.2 Animal experiments 
Weight- and gender-matched mice backcrossed for at least 6 generations were used 
at an age of 8 to 14 weeks for all experiments. For experiments including application 
of recombinant murine IL-22 and anti-IFNAR antibody or DSS experiments equal 
numbers (min. n=5 per genotype) of male and female animals were employed. 
Procedures involving animal care were conducted in conform to national and 
international laws and policies and appropriate permission. All experiments were 
carried out in accordance with the guidelines for Animal Care of the Kiel University 
and the University of Cambridge (for experiments involving Atg16l1ΔIEC/Xbp1ΔIEC 
mice). Mice were sacrificed by cervical dislocation. For mRNA and protein extraction, 
tissues were snap-frozen in liquid nitrogen and stored at -80°C.  
3.2.2.1 Systemic administration of IL-22 in Atg16l1fl mice 
Age- and gender-matched wild type (Atg16l1fl) mice at the age of 8-14 weeks 
received intraperitoneal administration of 2 μg of recombinant murine IL-22 (rmIL-22, 
Peprotech, Rocky Hill, United States) dissolved in 200 μl sterile PBS or equal 
volumes of sterile PBS without rmIL-22 (with n=3 animals per treatment group) once. 
Mice were sacrificed after 24 h post-injection. Crypts from small intestines and colons 
were collected and subsequently snap frozen and stored at -80°C for further analysis.  
The described animal experiment was approved by the Animal Investigation 
Committee of the University Hospital Schleswig-Holstein (Campus Kiel; acceptance 
no.: V 242-72241.121-33 (125-9/13)).  
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3.2.2.2 Systemic administration of IL-22 and anti-IFNAR antibody and 
DSS colitis in Atg16l1ΔIEC mice 
Age- and gender-matched Atg16l1fl and Atg16l1ΔIEC mice at the age of 8-14 weeks 
received intraperitoneal administration of 2 μg of recombinant murine IL-22 (rmIL-22 
Peprotech, Rocky Hill, United States) dissolved in 200 μl sterile PBS or equal 
volumes of sterile PBS without rmIL-22 (with n=5-8 animals per treatment group) on 
6 or 10 consecutive days, respectively. In an additional treatment group, Atg16l1ΔIEC 
mice received both rmIL-22 and a neutralising anti-IFNAR antibody (MAR1-5A3, 
BioXcell, West Lebanon, United States) (170) intraperitoneally, while anti-IFNAR was 
administered on the indicated experimental day after the dextran sodium sulphate 
(DSS) treatment. Body weight was assessed on a daily base. For induction of 
experimental acute colitis, a myriad of well-established protocols exists (171). In this 
study, mice were supplied with 2 % DSS dissolved in autoclaved tap water in place of 
regular drinking water (n=5-8 animals per treatment group). Dependent on the 
experimental scheme, 2 % DSS were supplied either for 4 days before sacrifice or for 
5 days followed by 5 days of regular drinking water before sacrifice. Organs and 
isolated intestinal crypts were collected and subsequently snap frozen and stored at -
80°C for further analysis. For histological analysis, intestinal tissues were fixed in 
10% formalin at 4°C overnight for further processing as described below.  
The described animal experiments were approved by the Animal Investigation 
Committee of the University Hospital Schleswig-Holstein (Campus Kiel; acceptance 
no.: V 242-72241.121-33 (125-9/13) including a notification of amendment).  
3.2.2.3 Systemic administration of IL-22 in Atg16l1ΔIEC/Xbp1ΔIEC mice 
Age- and gender-matched Atg16l1fl/Xbp1fl or Atg16l1ΔIEC/Xbp1ΔIEC mice at the age of 
8 to 12 weeks were treated with either 2 µg rmIL-22 or PBS via intraperitoneal 
injection (n=5-8 animals per treatment group) every other day for 13 days (7 
injections in total) before being sacrificed for histological assessment and intestinal 
epithelial cell isolation as described below. The described animal experiments were 
approved by the School of Clinical Medicine, Central Biomedical Resources 
(University of Cambridge) after provision of a regulated procedures study plan and a 
hazardous substance risk assessment according to UK standards. The internal study 
number allocated was 2560-54 (MT). 
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3.2.3 Isolation of primary intestinal epithelial tissue and organoid 
cultures 
Isolation of primary epithelial cells, especially for long-term culture purpose and 
irrespective of genetic background was approved by the Animal Investigation 
Committee of the University Hospital Schleswig-Holstein (Campus Kiel; acceptance 
no.: V 312-72241.121-33 (Internal no: 716)) if not included within other approved 
animal investigation proposals.  
3.2.3.1 Isolation of primary intestinal epithelial cells and crypts 
To obtain epithelial tissue from murine intestine, different isolation methods were 
applied. In general, mice were euthanised and the intestine was isolated. After 
removal of Peyer’s patches and mesenteric fat the intestines were longitudinally 
opened and flushed with ice-cold PBS.  
For intestinal epithelial scrapings, the intestinal epithelium was collected by scraping 
off the superficial mucosa using a glass slides and then snap frozen in liquid nitrogen 
for further analysis. 
For isolation of intestinal epithelial cells, intestines were cut into small pieces, 
transferred into 50 ml falcons and incubated in HBSS containing 1mM DTT for 10 min 
at room temperature with intermittent shaking to gently remove luminal mucus. 
Supernatant was removed and tissue was washed with PBS once and then digested 
with dispase (1 U/ml in RPMI with 2% FBS) for 30 minutes at 37°C whilst shaking 
(250 rpm). Debris was removed with a 100μm cell strainer, and cells were collected 
by centrifugation for 5 min at 1500rpm.  
The isolation of small intestinal crypts was established by Sato et al. (172) in order to 
establish long-term cultures of intestinal organoids. Based on the protocol used by 
Yilmaz et al. (96), intestines were flushed, cut open longitudinally, dissected into 
pieces of less than 0.5 cm of length and incubated on ice for 10 minutes in 10 mM 
EDTA dissolved in PBS whilst intermitting shaking. After sedimentation, the 
supernatant containing detritus, mucus and villi was discarded and 10 mM EDTA was 
substituted again. After three repeats, 4°C cold PBS was substituted to the small 
intestine pieces. The suspension was shaken vigorously for 30 seconds, incubated 
on ice for 5 minutes. This procedure was repeated to detach intestinal crypts from the 
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lamina propria. The suspensions were filtered through a cell strainer with 100 μm 
pores twice to separate intestinal crypts from the villi fraction. Crude preparation, 
including five repetition steps of shaking and only one step of straining, increased the 
amount of villi and lamina propria cells. This was used to investigate overall mucosa 
cells.  
Calculation of crypt numbers in the suspension was performed by microscopic 
assessment of crypt counts in a 5 µl-droplet of suspension. After centrifugation with 
300 x g at 4°C, the pellet contains intestinal crypts which were snap frozen for further 
analysis or used for organoid cultures.  
3.2.3.2 Establishment of intestinal organoid cultures 
For the establishment of intestinal organoids, the pelleted crypt fraction after the 
isolation described above was suspended in a mixture of Matrigel® (BD 
Bioscience/Heidelberg, Germany) and ice-cold PBS (2:1) to a concentration of 5-10 
crypts/1 µl gel mix. 100 µl of the suspension were plated out onto pre-cooled 24-well 
plates and incubated at 37°C for 15 minutes to let the gel polymerise. Afterwards, 
1000 µl of intestinal stem cell medium based on the protocol of Sato et al. were 
added. In essence, the medium based on Advanced DMEM/F12 (ADF) medium 
contained 10 % FBS, 10 mM HEPES, 1 % penicillin/streptomycin, murine EGF, 
murine Noggin and human R-Spondin 1 (see figure 1-2) (172). Medium was changed 
every other day and organoids were passaged every five to eight days. For 
passaging organoids, medium was removed and the well was flushed with 1 ml of 
ice-cold PBS. After pipetting up and down for 5 to 10 times the organoid-containing 
gel dissociated from the well and suspensions were collected in a 15 ml falcon. After 
centrifugation at 300 x g for 5 minutes the supernatant and excessive Matrigel were 
removed, leaving a loose pellet of organoids which was then vigorously suspended in 
100 µl of cold PBS to break down organoids to single crypt structures. Afterwards, 
crypts were again seeded out in 2:1 Matrigel/PBS mix. Organoids were subjected to 
stimulation experiments after a minimum of two passages. Cryopreservation and 
thawing of organoids was performed according to manufacturer’s protocol of 
StemCell Technologies using CryoStor™ CS10 (catalogue number #07930).  
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3.2.4 Quantification of cell death in intestinal organoids 
Organoids derived from mice of indicated genotypes were seeded out into 24-well 
plates. After approximately three to five days, organoids reached a size with multiple 
crypt-like buds and were treated with indicated stimulants for indicated time. 
To evaluate epithelial cell death, medium was changed and the gel was washed once 
with PBS. The gel was collected in 1.5 ml tubes, suspended in 1 ml of ice-cold PBS 
and the pelleted after centrifugation at 4°C for 5 minutes at 400 x g. Supernatants as 
well as the upper layers of the gel remnants were removed. Lower layers of the gel 
pellet containing organoids were incubated in TrypLE Express (ThermoFischer 
Scientific, Steineich, Germany) for 5 min at 37°C to dissociate cells, followed by 
washing steps using ice-cold PBS. 250,000 cells were incubated in staining solution 
containing 2 µl PI in 100 µl PBS each and then subjected to flow cytometry analysis 
using BD FACSCalibur™ (San Jose, United States) and BD CellQuest™ Pro 
Software. The gating strategy involved plotting FL-2H for PI fluorescence intensity 
against forward scatter (FSC) to distinguish PIhigh vs PIlow populations which are 
assumed to be dead vs living cells. These gates excluded cellular clumps with did not 
dissociate well after TrypLE Express treatment. Dead cells were then first quantified 
as fraction of dead cells (= dead cells/total single cells). Cell death induction by 
stimulants were then determined as % change dead cells, while the fraction of dead 
cells in the treatment control wild type organoids served as the baseline cell death 
rate (% change dead cells = fraction of dead cells after treatment – fraction of wild 
type dead cells at baseline).  
To visualise dead cells in organoids, 1 µl of PI was added to 500 µl medium for 4 
hours. Medium was then removed and replaced by PBS. Merged images with a 
bright-field image overlaid by a RFP-filtered fluorescence channel capture (red 
fluorescent cells indicate PI+ dead cells) were generated using Zeiss Axio Vert.A1 
observer (Jena, Germany) and Zeiss AxioVision LE software. Images are shown at 
indicated magnification.  
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Figure 3-1: Quantification and visualisation of cell death in intestinal organoids 
(a) FACS plot of wild type organoids treated with tunicamycin (1 µg/ml) for 24h or DMSO 
control, with or without prior incubation with PI (2 µl/100 µl PBS) for 10 minutes. FL-2H was 
plotted against FSC-H. Gate includes PIhigh cells, which are considered as dead. (b) 
Corresponding analysis of gated PIhigh cells, each group n=1. (c) Calculated % change dead 
cells compared to DMSO controls. (d) Visualisation of cell death in organoids from the same 
experiment as in (a). Bright field images, RFP-filtered fluorescence detection captions (for PI) 
and merged images are shown. Bars indicate 100 µm.  
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3.2.5 Cell culture 
HT-29 and Caco-2 human colorectal adenocarcinoma cells were seeded in 6-well, 
12-well and 24-well plates. Using CRISPR/Cas9 technology (173), an ATG16L1 
deficient Caco-2 cell line was established by Dr. Johannes Kuiper and kindly 
provided for this work. Cells were cultured in DMEM + 10 % FCS or MEM + 20 % 
FCS, respectively, until a fully confluent cellular monolayer established. Prior to 
stimulation, cells were serum-starved by incubating DMEM + 1% medium or MEM + 
1% FCS for 24 h.  
3.2.6 Scratch assays 
Scratch assays were performed based on the protocol of Liang et al. (174) In detail, 
epithelial cells were seeded out into 6- or 12-well plates and cultured until fully 
confluent cellular monolayers established. The medium was removed and cells were 
gently washed with 37°C warm PBS once. Using a scalpel, a line was cut on the 
bottom of each well to support later re-identification of assessed wound areas. To 
create an epithelial wound, a P100 pipette tip was used to rapidly scratch the cellular 
layer (Figure 3-2). The wounds were then washed with warm PBS for three times to 
remove dissociated cells before incubation in proper medium and condition. Epithelial 
wound closure was assessed by imaging using Zeiss Axio Vert.A1 (Jena, Germany) 
and digital measurement of the cell free area using AxioVision LE (Zeiss) software. 
The relative wound closure after indicated time interval is calculated as followed:  
Relative wound closure = 1 – (wound area/starting wound area).    
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Figure 3-2: Conception of epithelial scratch assays 
(a) Scheme of epithelial scratch assays using a P100 pipette tip. Cell lines were cultured until 
confluence before wounding. (b) Unstimulated HT-29 cell layer directly after wounding and 
after 24h of regeneration. Red bars indicate 100 µm.  
3.2.7 Histopathological analyses of murine intestinal tissue 
After cervical dislocation, the entire small intestine or colon was excised and 
separated longitudinally into two equal parts. The longitudinal section was rolled up, 
starting with the distal part thereby having the distal ileum at the very inner layer and 
the proximal intestine at the very outer layer. The entire specimen was fixed in 10% 
formalin. Paraffin sections were cut and stained with hematoxylin/eosin. Histological 
scoring was performed in a blinded fashion by two independent observers. The 
histological score displays the combined score of inflammatory cell infiltration and 
tissue damage as described elsewhere (175). A semi-quantitative scoring system 
was used for the assessment of spontaneous intestinal inflammation, computed as a 
sum of five histological subscores. The histological subscores were determined as 
followed (for each parameter: 0, absent; 1, mild; 2, moderate; 3, severe): 
mononuclear cell infiltrate, crypt hyperplasia, epithelial injury/erosion, granulocyte 
infiltrates and transmural inflammation (0, absent; 1, submucosal; 2, one focus 
extending into muscularis and serosa; 3 up to five foci extending into muscularis and 
serosa; 4, diffuse).  
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3.2.8 Immunohistochemistry and immunofluorescence 
For immunohistochemical (IHC) and immunofluorescence (IF) staining, 5 µm 
sections of paraffin-embedded colon/ileum swiss rolls were deparaffinised with Xylol 
substitute (Roth) and incubated in citric buffer for 3 minutes.  
For IHC, sections were blocked with blocking serum (Vectastain ABC Kit) for 20 
minutes. Primary antibodies (anti-γH2AX, rabbit, Cell Signalling Technologies 
(Leiden, The Netherlands), #9718, used in 1:1,000 dilution) were incubated 
overnight. Sections were washed, incubated with biotinylated secondary antibodies 
and afterwards with DAB substrate (Vectastain ABC Kit).  
For IF staining, sections were blocked in PBS containing 5% BSA and 0.2% Triton-X 
for 30 minutes after removal of citric buffer and before incubation of a primary 
antibody overnight at 4°C (see table 1). Secondary antibodies conjugated with 
fluorophores were added after washing steps with PBS for 45 minutes. Then, tissue 
was then counterstained with DAPI and DRAQ5 and then mounted with fluorescence 
mounting medium (DAKO). For IF staining of Caco-2 cells, cells were fixed on cover 
slides using 4 % paraformaldehyde for 30 minutes at room temperature. After 
washing steps, cells were permeabilised for 3 minutes at room temperature using 
PBS containing 1 % Triton X-100 and 5 % BSA. Cells were blocked using 5 % goat 
serum for at least 60 minutes at room temperature. The further staining procedure 
was identical to the IF protocol for tissues.  
Table 1: Antibodies used for immunofluorescence staining 
Primary 
antibody 
Host 
specificity 
Working 
dilution 
Company Article number 
dsDNA mouse 1:1,000 
Santa Cruz Biotechnology 
(Heidelberg, Germany) 
sc-58749 
phospho-
TBK1 
rabbit 1:1,000 
Cell Signalling Technologies 
(Leiden, The Netherlands) 
#13647 
E-cadherin 
(clone 36) 
mouse 1:200 
BD Biosciences (Heidelberg, 
Germany) 
#610182 
 
Secondary 
antibody 
Host 
specificity 
Working 
dilution 
Company Article number 
anti-mouse 
Alexa Fluor 
488 
goat 1:10,000 
Invitrogen 
(Darmstadt, Germany) 
A11029 
anti-rabbit 
Alexa Fluor 
555 
goat 1:10,000 
Invitrogen 
(Darmstadt, Germany) 
A21430 
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For TUNEL assay, slides were subjected to ApopTag® Plus Peroxidase In Situ 
Apoptosis Detection Kit (Merck Millipore) according to manufacturer’s protocol. 50 
randomly distributed intestinal crypts were analysed for TUNEL+ cells and numbers 
were normalised to the number of crypts. Slides were visualised by an AxioImager Z1 
microscope (Zeiss, Jena, Germany). Pictures were captured by a digital camera 
system (AxioCam HrC/HrM, Zeiss). Measurements were made using a semi-
automated image analysis software (AxioVision version 08/2013). 
3.2.9 Protein detection and analysis 
3.2.9.1 Protein extraction and quantification 
Cells and tissues were lysed using 40-100 µl SDS-based DLB buffer + 1 % HaltTM 
Protease inhibitor cocktail (ThermoFischer Scientific, Steineich, Germany) before 5 
minutes incubation at 95°C and followed by sonification for 5 seconds. To remove 
cell remnants, lysates were centrifuged at 16.000 x g for 15 minutes at 4°C and 
supernatants were transferred into a new tube. For protein extraction of organoids, 
Matrigel was removed by several centrifugation steps at 4°C followed by lysis as 
described above. If not in use, lysates were stored at -80°C.  
For quantification of protein concentrations, the colorimetric DC™ Protein Assay (Bio-
Rad, Munich, Germany) based on the Lowry method (176) was used according to the 
manufacturer’s protocol. The absorbance at 750 nm was measured using the 
microplate reader Infinite M200 Pro (Tecan, Männedorf, Switzerland) and the 
appropriate software i-control™ 1.9 (Tecan, Männedorf, Switzerland).  
3.2.9.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Before immunoblot analysis, equal amounts of lysates (15-20 µg of total protein) 
were supplemented with 5x SDS loading dye and heated at 95°C for 5 minutes. 
Lysates were then transferred on self-prepared polyacrylamide gels before 
electrophoresis. The used gel consists of a 12 or 15 % separation gel, which is 
overlaid by a 3 % stacking gel (Table 2).  
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Table 2: Formulation of used stacking and separation gel for SDS-PAGE 
components 12 % separation gel 15 % separation gel 3 % stacking gel 
distilled water 3.5 ml 2.5 ml 1.95 ml 
buffer 2.5 ml (separation) 2.5 ml (separation) 0.75 ml (stacking) 
30% bisacrylamide 
(35.7:1) 
4 ml 5 ml 0.3 ml 
TEMED 10 µl 10 µl 3 µl 
10 % APS 100 µl 100 µl 30 µl 
 
Electrophoresis was performed in 1x Tris/Glycine/SDS (TGS) buffer at 15 mA for 30 
minutes followed by 60 minutes at 30 mA.  
3.2.9.3 Immunoblot analysis 
After electrophoretic separation, proteins were transferred onto polyvinylidene 
fluoride (PVDF) membranes (GE Healthcare, Munich, Germany) using a semi-dry 
immunoblotting technique at 0.1 A for 45 minutes. Protein loaded membranes were 
blocked with 5 % blotting grade blocker (non-fat dry milk, Bio-Rad, Munich, Germany) 
or bovine serum albumin (BSA) in 1x Tris-buffered saline (TBS) supplemented with 
0.1 % Tween 20 (T/TBS) for 1 hour at room temperature. Membranes were then 
incubated with specific primary antibodies over night at 4°C (Table 3).  
Table 3: Primary antibodies used for immunoblot analysis  
Primary 
antibody 
Host 
specificity 
Working 
dilution 
Company Article number 
ATG16L1 mouse 1:500 
MBL International  
(Woburn, United States) 
M150-3 
STING rabbit 1:1,000 
Cell Signaling Technologies 
(Leiden, The Netherlands) 
#13647 
phospho-
TBK1 
rabbit 1:1,000 
Cell Signaling Technologies 
(Leiden, The Netherlands) 
#5483 
TBK1 rabbit 1:1,000 
Cell Signaling Technologies 
(Leiden, The Netherlands) 
#3504 
LC3BI/II rabbit 1:1,000 
Novus Biologicals  
(Cambridge, United Kingdom) 
NB100-2331 
β-Actin mouse 1:10,000 
Sigma  
(Munich, Germany) 
A-5441 
GAPDH mouse 1:10,000 
Santa Cruz Biotechnology 
(Heidelberg, Germany) 
sc-59541 
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Afterwards, membranes were washed with T/TBS three times and incubated to an 
appropriate horseradish peroxidase (HRP)-conjugated secondary antibody for 1 hour 
at room temperature (Table 4).  
Table 4: Secondary antibodies used for immunoblot analysis 
Secondary 
antibody 
Host 
specificity 
Working 
dilution 
Company Article number 
rabbit- 
HRP 
sheep 1:3,000 
GE Healthcare  
(Hamburg, Germany) 
NA931V 
mouse-
HRP 
sheep 1:3,000 
GE Healthcare  
(Hamburg, Germany) 
NA934V 
 
Membranes were washed with T/TBS three times, again and protein was detected by 
chemiluminescence using Amersham ECL™ Prime Western Blot Detection Reagents 
(GE Healthcare, Hamburg, Germany) or Pierce ECL™ Plus Western Blotting 
Substrate (ThermoFischer Scientific, Darmstadt, Germany). Chemiluminescence of 
the protein bands were captured on Amersham Hyperfilm ECL (GE Healthcare, 
Hamburg, Germany) which were developed using Curix 60 (AGFA, Mortsel, 
Belgium). If necessary, membrane stripping was performed in 50 ml stripping buffer 
containing 0.6 % β-mercaptoethanol for 20-40 minutes at 55°C.  
3.2.10 Enzyme-linked immunosorbent assay (ELISA) 
To determine human IL-8 concentrations secreted from stimulated cell cultures, 
supernatants were subjected to the human IL-8 ELISA Kit according to 
manufacturer’s protocol from ThermoFischer Scientific (Darmstadt, Germany).  
3.2.11 mRNA extraction, cDNA synthesis and gene expression 
analysis  
mRNA isolation of PBS washed cells, snap frozen tissue and PBS washed Matrigel 
containing organoids was performed using commercial RNA isolation kit (RNEasy Kit 
Mini, Qiagen, Hilden, Germany). RNA concentration was measured using the 
NanoDrop spectrometer ND1000 (PeqLab, Erlangen, Germany). cDNA synthesis 
was performed using RevertAid Premium cDNA Synthesis Kit (ThermoFischer 
Scientific, Darmstadt, Germany) according to manufacturer’s protocol. Gene 
expression analysis was subjected to the cDNA samples using SYBR Green qRT-
PCR or TaqMan assays (Table 5) which were purchased from Applied Biosystems 
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(Darmstadt, Germany). Primer sequences were retrieved using Primer3 software 
version 0.4.0(177, 178), except for those individually referenced (Table 6). The 
design criteria involved exon-exon span, a length of 20-25 bases, an optimal 
annealing temperature of 60°C and an amplicon size of 200-400 basepairs (bp). 
Synthesis of primers was carried out by Microsynth (Lindau, Germany).  
Table 5: List of TaqMan Assays used for quantitative real-time PCR 
 
Gene Name Species TaqMan Probe ID 
Reg3g Mus musculus 01181783 
Reg3b Mus musculus 00440616 
Atg16l1 Mus musculus 00513085 
Lgr5 Mus musculus 00438905 
Actb Mus musculus 00607939 
 
Table 6: List of primers used for quantitative real-time PCR  
 
Primer Sequence Reference 
mu_Actb for 5’- GATCGGTGGCTCCATCCTGGC  
mu_Actb rev 5’- CGCAGCTCAGTAACAGTCCGCC  
mu_Gapdh for 5’- CCGGGGCTGGCATTGCTCTCA  
mu_Gapdh rev 5’- CTTGCTCAGTGTCCTTGCTGGGG  
mu_Xbp1 for 5’- AGCAGCAAGTGGTGGATTTG Kaser et al. (93) 
mu_Xbp1 rev 5’- GAGTTTTCTCCCGTAAAAGCTGA Kaser et al. (93) 
mu_splicedXbp1 for 5’- ACACGCTTGGGAATGGACAC Iwakoshi et al. (179) 
mu_splicedXbp1 rev 5’- CCATGGGAAGATGTTCTGGG Iwakoshi et al. (179) 
mu_Atf4 for 5’- ATGGCCGGCTATGGATGAT Fribley et al. (180) 
mu_Atf4 rev 5’- CGAAGTCAAACTCTTTCAGATCCATT Fribley et al. (180) 
mu_Grp94 for 5’- TGGGTCAAGCAGAAAGGAGG  
mu_Grp94 rev 5’- TCTCTGTTGCTTCCCGACTTT  
mu_Cxcl1 for 5’- GCTGGGATTCACCTCAAGAA Ather et al. (181) 
mu_Cxcl1 rev 5’- TGGGGACACCTTTTAGCATC Ather et al. (181) 
mu_Cxcl10 for 5’- GCCGTCATTTTCTGCCTCA Luo et al. (182) 
mu_Cxcl10 rev 5’- CGTCCTTGCGAGAGGGATC Luo et al. (182) 
mu_Tmem173 for 5’- AGTAGAGAGCTTTGGGGCCT  
mu_Tmem173 rev 5’- TTCTGAATGGGGAGACAGCAG  
mu_Ifit1 for 5’- GAACCCATTGGGGATGCACAACCT Hasan et al. (183) 
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mu_Ifit1 rev 5’- CTTGTCCAGGTAGATCTGGGCTTCT Hasan et al. (183) 
mu_Ifit3 for 5’- TGGCCTACATAAAGCACCTAGATGG 
Pokatayev et al. 
(184) 
mu_Ifit3 rev 5’- CGCAAACTTTTGGCAAACTTGTCT 
Pokatayev et al. 
(184) 
mu_Tnf for 5’- TCACACTCAGATCATCTTCTC Lian et al. (185) 
mu_Tnf rev 5’- AGACTCCTCCCAGGTATATG Lian et al. (185) 
mu_Olfm4 for 5’- CATCAGCGCTCCTTCTGTGA  
mu_Olfm4 rev 5’- TCCTTGGCCATAGCGAATCC  
hu_ACTB for 5’- AGCCTCGCCTTTGCCGATCC Fan et al. (186) 
hu_ACTB rev 5’- ACATGCCGGAGCCGTTGTCG Fan et al. (186) 
hu_GAPDH for 5’- GGCATGGCCTTCCGTGTCCC 
Niedwziecka et al. 
(187) 
hu_GAPDH rev 5’- TGCCAGCCCCAGCGTCAAAG 
Niedwziecka et al. 
(187) 
hu_XBP1 for 5’- CCTGGTTGCTGAAGAGGAGG Chen et al. (188) 
hu_XBP1 rev 5’- CCATGGGGAGATGTTCTGGAG Chen et al. (188) 
hu_splicedXBP1 for 5’- GCTGAGTCCGCAGCAGGTG Ma et al. (189) 
hu_splicedXBP1 rev 5’- GCTGGCAGGCTCTGGGGAAG Dery et al. (190) 
hu_ATF4 for 5’ - AGATGACCTGGAAACCATGC Wang et al. (191) 
hu_ATF4 rev 5’- AGGGATCATGGCAACGTAAG Wang et al. (191) 
hu_GRP94 for 5’- TGCCAAGGAAGGAGTGAAGT Wang et al. (191) 
hu_GRP94 rev 5’- GTTGCCAGACCATCCGTACT Slepak et al. (192) 
Reactions were carried out on the Applied Biosystems 7900HT Fast Real-Time PCR 
System (Applied Biosystems, Foster City, USA), and relative transcript levels were 
determined using ACTB/Actb (TaqMan and SYBR Green) and GAPDH/Gapdh 
(SYBR Green) as a housekeeper. 
3.2.12 Transcriptomics analysis 
RNA sequencing (RNAseq) was conducted on small intestinal organoids derived 
from Atg16l1ΔIEC and Atg16l1fl mice (n=4) treated with recombinant murine IL-22 (1 
ng/ml) or controls. Samples were sequenced on HiSeq3000 (Illumina, San Diego, 
United States) using Illumina total RNA stranded TruSeq protocol. An average of ~28 
million 150-nt paired-end reads was sequenced for each sample. Raw reads were 
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pre-processed using cutadapt (193) to remove adapter and low quality sequences. 
RNAseq reads were aligned to the mm10/Ensemble (GrCm38) reference genome 
with TopHat2 (194).  Gene expression values of the transcripts were computed by 
HTSeq (195). Differential gene expression levels were analysed and visualised by 
the Bioconductor package DESeq2(196). The overall effect of IL-22 treatment on 
organoid cells of Atg16l1ΔIEC and Atg16l1fl mice was obtained by multifactorial 
experimental design of DESeq2. Likelihood ratio test was used to assess the 
significant differentially expressed genes (DEG) of IL-22 treatment interaction of 
Atg16l1ΔIEC and Atg16l1fl mice (p < 0.01). Venn diagrams were drawn using 
VennDiagram package in R (197).  To gain insight into the nature of DEGs uniquely 
expressed in Atg16l1ΔIEC and Atg16l1fl mice upon IL-22 treatment (up- and down- 
regulated), Gene Ontology (GO) terms obtained within the category of biological 
processes using the InnateDB database (www.innatedb.com) were identified (198).  
3.2.13 Transcription factor binding site analysis 
Over-represented transcription factor binding sites (TFBS) in the promoter region of 
DEGs uniquely expressed (up- and down-regulated) in Atg16l1ΔIEC and Atg16l1fl/fl 
mice upon IL-22 treatment were identified by InnateDB (198), integrating predicted 
TFBS data from the CisRED database (www.cisred.org) (199).   
3.2.14 Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING) 
To identify functional clusters and signalling branches within the DEG found in the 
transcriptomic analyses, results were subjected to gene-gene interaction analysis 
using web applications of Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING) (200).  
3.2.15 Statistical analysis 
Statistical analysis was performed using GraphPad Prism (version 5.03) for Windows 
software (GraphPad Software, San Diego, CA). Statistical significance was evaluated 
by the Mann–Whitney U test for nonparametric data or the Student t-test for 
parametric data unless indicated otherwise. P values less than 0.05 were considered 
statistically significant. 
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4   Results 
4.1 IL-22 induces ER stress in intestinal epithelial cells 
IL-10, a cytokine similar to IL-22 in structure, can potentially suppress epithelial ER 
stress (162). Therefore, I investigated the role of IL-22 in epithelial ER stress 
responses. ER stress levels were assessed via gene expression analysis of 
commonly used ER stress markers encompassing each branch of the UPR using 
quantitative real-time PCR. 24 h of IL-22 treatment (100 ng/ml) increased expression 
of sXBP1, ATF4 and GRP94, indicating global UPR activation including the 
IRE1/XBP1 branch, the PERK/ATF4 branch and the ATF6 (GRP94) (figure 4-1).  
 
Figure 4-1: IL-22 induces ER stress in HT-29 cells 
HT-29 cells were treated with either PBS as a control or 100 ng/ml IL-22 for the indicated 
time in hours (n=3 each). Splicing ratio of XBP1 and mRNA expression ATF4 and GRP94 
were analysed by SYBR green qPCR and normalised to ACTB expression. Data are shown 
as mean ± s.e.m. and were tested for statistical significance using unpaired Student’s t-test.  
* p<0.05, ** p<0.01 vs. ctrl. 
To elucidate whether IL-22 augmented chemically induced ER stress in epithelial 
cells, HT-29 cells were treated with IL-22 (100 ng/ml) 24 or 6 h before or 
simultaneously with either ER stressing agent tunicamycin (1 µg/ml) or equal 
volumes of DMSO. Tunicamycin strongly induced all investigated ER stress marker 
on transcriptional level (figure 4-2a). Pre-treatment of HT-29 cells with IL-22 induced 
a substantial exacerbation of tunicamycin-induced ER stress, indicating that 
chemically induced ER stress coincided with physiological ER stress upon cytokine 
signalling. We validated these findings for murine cells using Xbp1fl mice-derived 
stable long-term organoid cultures. After two passages and a total of 12 days of 
culture, organoids were treated with IL-22 (100 ng/ml) for 24 h and tunicamycin (0.5 
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µg/ml) for 6 h (figure 4-2b). Analysis of ER stress markers confirmed IL-22 
aggravated tunicamycin-induced ER stress. 
 
Figure 4-2: IL-22 augments tunicamycin-induced ER stress in intestinal epithelial cells 
(a) HT-29 cells received IL-22 (100 ng/ml) or PBS for the indicated time and tunicamycin (1 
μg/ml) or both for 6 h (n=3 each). PBS or DMSO, respectively, served as stimulation controls. 
Expression levels of sXBP1, ATF4 and GRP94 were analysed by SYBR green qPCR and 
normalised to ACTB expression. (b) Small intestinal organoids were derived from wild type 
(Xbp1fl) mice and cultured for 12 days received rmIL-22 (100 ng/ml) for the indicated time 
and tunicamycin (0.5 µg/ml) or both for 6 h (n=3 each). PBS or DMSO, respectively, served 
as stimulation controls. Expression levels of sXbp1, Atf4 and Grp94 were analysed by SYBR 
green qPCR and normalised to Gapdh expression. Data are shown as mean ± s.e.m. and 
were tested for statistical significance using unpaired Student’s t-test. * p<0.05, ** p<0.01,  
*** p<0.001. 
To test whether IL-22 induced epithelial ER stress in vivo we stimulated wild type 
(Atg16l1fl) mice with IL-22 (2 μg) for 24 h and analysed small intestinal crypt  ER 
stress marker expression. IL-22 upregulated ER stress markers sXbp1, Atf4 and 
Grp94 (figure 4-3). However, Atf4 and Grp94 mRNA transcript levels were not 
significantly upregulated by IL-22 treatment.  
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Figure 4-3: IL-22 induces ER stress in intestinal crypts 
Small intestinal crypts from Atg16l1fl mice were collected after treatment with recombinant 
murine IL-22 (2 μg) 24 hours before sacrifice (n=3 each). Afterwards, mRNA was extracted 
and transcribed to cDNA before being analysed for gene expression of sXbp1, Atf4 and 
Grp94 by SYBR green qPCR and normalised to Gapdh expression. Data are shown as mean 
± s.e.m. and were tested for statistical significance using unpaired Student’s t-test. ** p<0.01. 
IL-23 is a critical upstream regulator of IL-22 production (75). To test, whether 
epithelial loss of Il23r affects mucosal IL-22 production, crypts from colon and small 
intestine were crudely isolated (isolates contained lamina propria cells) and treated 
with IL-23 (50 ng/ml) for 3 hours. Gene expression analysis revealed significant loss 
of Il22 expression in Il23r∆IEC isolates, in particular in the small intestine (figure 4-4a). 
Therefore, Il23r∆IEC mice represented a proper model for impaired small intestinal IL-
22 signals. To test, whether this affects epithelial ER stress, crypts isolated from 
small intestine and colon of Il23r∆IEC mice were subjected to gene expression 
analysis for sXbp1, Atf4 and Grp94. Indeed, epithelial UPR markers were significantly 
lower expressed in Il23r∆IEC small intestines compared to their genotype controls 
(figure 4-4b). Interestingly, colonic crypts displayed similar ER stress levels 
irrespective of Il23r genotype, pointing towards an ER stress-inducing role of IL-22 
restricted to the small intestine.  
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Figure 4-4: Absence of mucosal IL-22 reduces epithelial UPR in the small intestine  
(a) Crude crypt isolates from small intestines and colons from Il23rfl and Il23r∆IEC mice were 
incubated in RPMI and treated with either PBS or rmIL-23 (50 ng/ml) for 3 h. Gene 
expression of Il22 was analysed by SYBR green qPCR and normalised to Gapdh expression 
(n=3 each). (b) Intestinal crypts from small intestines and colons from Il23rfl and Il23r∆IEC mice 
were analysed for gene expression of sXbp1, Atf4 and Grp94 by SYBR green qPCR and 
normalised to Gapdh expression (n=3 each). Data are shown as mean ± s.e.m. and were 
tested for statistical significance using unpaired Student’s t-test. * p<0.05, ** p<0.01, *** 
p<0.001. 
To test whether the ER stress induction by cytokines is specific to IL-22, HT-29 cells 
were treated with IL-10 (100 ng/ml) for 24 h and tunicamycin (1 μg/ml) for 6 h. ER 
stress levels were assessed by gene expression analysis of UPR target genes 
sXBP1 and ATF4. IL-10 did not prevent ER stress in this setting (figure 4-5), despite 
the previously proposed protective role of IL-10 (162). Collectively, these data point 
toward an IL-22 specific role in the adjustment of ER function in the intestinal 
epithelium.  
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Figure 4-5: ER stress induction in intestinal epithelial cells is specific for IL-22 
HT-29 cells received recombinant human IL-10 (100 ng/ml) for 24 h (n=3 each) and 
tunicamycin (1 µg/ml) for 6 h. PBS or DMSO, respectively, served as stimulation controls. 
Expression levels of sXBP1 and ATF4 were analysed by SYBR green qPCR and normalised 
to ACTB expression. Data are shown as mean ± s.e.m. and were tested for statistical 
significance using unpaired Student’s t-test. * p<0.05, ** p<0.01, *** p<0.001. 
4.2 IL-22 impedes epithelial regeneration in the context of 
ER stress 
Chronic ER stress can impede intestinal proliferation by suppressing intestinal 
stemness (201). To test the hypothesis that the pro-regenerative response of IL-22 
depend on the homeostatic state of the epithelial cell, the epithelial scratch assay as 
a model of epithelial regeneration was employed. In a first line of evidence, the 
models were tested whether they are amenable to study the growth-impeding role of 
ER stress in IEC`s. Directly after wounding, increasing concentrations of tunicamycin 
or a dimethyl sulfoxide (DMSO) control were added to the medium. After 24 h, 
tunicamycin suppressed wound closure in a dose-dependent manner (figure 4-6). 
Doses of 5 µg/ml of tunicamycin even led to further erosion of the epithelial layer.  
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Figure 4-6: Tunicamycin dose-dependently impedes epithelial wound closure 
(a) Scheme of epithelial scratch assays and an example of a wound in a HT-29 cell 
monolayer at time point 0 h and after 24 h. (b) HT-29 cells received indicated concentrations 
of tunicamycin for 24h (n=3 each). DMSO served as a stimulation control. Wound close 
relative to the starting wound area was assessed. Data are shown as mean ± s.e.m. and 
were tested for statistical significance using unpaired Student’s t-test. *** p<0.001.  
Next, effects of IL-22 on epithelial regeneration were assessed. HT-29 cells were 
treated with IL-22 directly after wounding. EGF or tunicamycin were added to the 
experiment as positive and negative controls for epithelial growth. IL-22 promoted 
wound closure until 24 h in line with the pro-regenerative role reported (56) (figure 4-
7). However, IL-22-induced wound closure speed declined in the following 24 h. By 
contrast, EGF treatment maintained epithelial growth for the entire observation period 
of 48 h.  These results suggest a complex, time-dependent role of IL-22 on epithelial 
regeneration. 
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Figure 4-7: Kinetic of wound closure of HT-29 cells after treatment with IL-22, 
tunicamycin and EGF 
HT-29 cells received rhIL-22, rhEGF (100 ng/ml each) or tunicamycin (1 µg/ml) directly after 
wounding, n=6 each. DMSO served as stimulation controls. Wound close relative to the 
starting wound area was assessed 8, 24 and 48 hours after scratch. Data are shown as 
mean of 6 replicates. 
To further evaluate the effect of IL-22 on ER stress-dependent growth inhibition of 
wounded epithelial layers, HT-29 cells were treated with IL-22 either for 24h before or 
simultaneously with epithelial wounding. Tunicamycin was added directly after 
wounding. In line with the previous finding, pre-treatment with IL-22 did not improve 
wound healing even if the cells received additional IL-22 after scratching (figure 4-
8a). Strikingly, IL-22 exacerbated tunicamycin-dependent wound closure inhibition, in 
concordance with an ER stress-potentiating role of IL-22 (see figure 4-2). To test 
whether the described impairment of wound closure is associated with pro-
inflammatory cytokine expression, supernatants from this experiment were analysed 
for human IL-8 levels via ELISA (figure 4-8b). In congruence with the wound healing 
experiments, IL-22 exacerbated tunicamycin-driven IL-8 expression, indicating an ER 
stress-dependent pro-inflammatory phenotype upon IL-22 treatment. Hence, IL-22 
has a context-dependent effect on epithelial regeneration. 
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Figure 4-8: IL-22 exacerbates tunicamycin-driven growth inhibition in HT-29 cells 
(a) HT-29 cells received rhIL-22 (100 ng/ml) either 24h before or directly after wounding. 
Tunicamycin (1 µg/ml) was added directly after wounding. PBS or DMSO served as 
stimulation controls, respectively. n=18 each. Wound close relative to the starting wound 
area was assessed 24 hours after scratch. (b) Supernatants collected from (a) 24 h after 
wounding were analysed for hIL-8 levels via ELISA (n=3 each). Data are shown as mean ± 
s.e.m. and were tested for statistical significance using unpaired Student’s t-test. * p<0.05,  
** p<0.01. 
4.3 ER stress induction by IL-22 is dependent on STAT3 
and autophagy 
To decipher the underlying mechanisms of IL-22-induced ER stress, we tested 
whether IL-22-induced ER stress depended on STAT3, the canonical downstream 
effector of IL-22 (56), HT-29 cells were treated with IL-22 and tunicamycin in the 
presence or absence of S3I-201, a chemical inhibitor of STAT3 (137). Indeed, STAT3 
inhibition reduced ER stress in HT-29 cells treated with IL-22 and tunicamycin (figure 
4-9a), indicating that deleterious IL-22 effects are mediated via canonical STAT3 
signalling. Homeostatic ER stress is balanced by induction of autophagy, and ER 
stress and autophagy are essential cross-compensatory mechanisms in IEC`s. Shifts 
in this balance may contribute to IBD pathogenesis (160). We therefore tested 
whether inhibition of mTOR, an established mechanism of autophagy induction (202), 
by rapamycin rescued IL-22-dependent ER stress. HT-29 cells were therefore treated 
with IL-22 and tunicamycin, with or without concomitant administration of rapamycin. 
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Rapamycin suppressed synergistically induced ER stress by IL-22 and tunicamycin 
(figure 4-9b).  
 
Figure 4-9: STAT3 and autophagy control IL-22-dependent ER stress 
HT-29 cells received (a) S3I-201 (iSTAT3, 5 µM) or (b) rapamycin (Rapa, 5 nM) for 48 h, IL-
22 (100 ng/ml) for 24 h and tunicamycin (1 µg/ml) for 6h (n=3 each). PBS or DMSO, 
respectively, served as stimulation controls. Expression levels of sXBP1 analysed by SYBR 
green qPCR and normalised to GAPDH expression. Data are shown as mean ± s.e.m. and 
were tested for statistical significance using unpaired Student’s t-test. * p<0.05, ** p<0.01. 
To further test, whether STAT3 inhibition or autophagy induction can reverse ER 
stress-dependent impairment of epithelial regeneration, either iSTAT3 or rapamycin 
were added prior to IL-22 treatment and epithelial scratch. In line with gene 
expression data, both iSTAT3 and rapamycin were able to rescue epithelial wound 
closure after IL-22 and tunicamycin challenge (figure 4-10). Rapamycin treatment 
also prevented IL-8 expression after IL-22 and tunicamycin challenge. Interestingly, 
addition of iSTAT3 did not alter IL-8 levels in supernatants of ER stressed HT-29 
cells, indicating a STAT3-independent activation of NF-κB signalling in this setting. 
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Figure 4-10: STAT3 inhibition and rapamycin prevent ER stress-dependent 
inflammatory phenotype 
(a) HT-29 cells received S3I-201 (iSTAT3, 5 µM) or rapamycin (Rapa, 5 nM) 48 h and rhIL-
22 (100 ng/ml) 24 h before wounding. Tunicamycin (1 µg/ml) was added directly after 
scratching. PBS or DMSO served as stimulation controls, respectively (n=18 each). Wound 
close relative to the starting wound area was assessed 24 hours after scratch. (b) 
Supernatants collected (a) 24 h after wounding were analysed for hIL-8 levels via ELISA 
(n=3 each). Data are shown as mean ± s.e.m. and were tested for statistical significance 
using unpaired Student’s t-test. * p<0.05, ** p<0.01, *** p<0.001. 
As previously described, autophagy restrains IRE-1 activity in order to prevent 
excessive ER stress-dependent NF-κB activation and subsequent inflammation 
(160). To test whether the ER stress potentiating role of IL-22 is due to inhibition of 
autophagy, HT-29 cells were treated with IL-22 and tunicamycin as before and an 
immunoblot against autophagy marker LC3β was performed. IL-22 and tunicamycin 
unexpectedly both led to increased conversion of LC3β-I to LC3β-II (figure 4-11). In 
conclusion, IL-22 induces ER stress-dependent autophagy and therefore ER stress 
potentiation is likely not due to autophagy inhibition. 
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Figure 4-11: IL-22-dependent ER stress induces autophagy 
HT-29 cells received rhIL-22 (100 ng/ml) for 24 h and tunicamycin (1µg/ml) for 6 h. PBS or 
DMSO, respectively, served as stimulation controls. Proteins were extracted, immunoblotted 
and analysed for LC3β. β-Actin served as a loading control. One representative immunoblot 
out of three independent experiments is shown.  
To test whether vice versa inhibition of autophagy mimics the effect of ER stress on 
epithelial regeneration, HT-29 cells were treated with bafilomycin A1 (BafA), a late 
stage autophagy inhibitor, in presence or absence of IL-22. Indeed, epithelial layers 
treated with IL-22 and BafA displayed significantly less wound closure after wounding 
(figure 4-12). IL-8 levels in the supernatants increased after BafA treatment, which 
however was not significantly affected by IL-22. Hence, autophagy inhibition mimics 
the wound closure impairing effect on tunicamycin. 
 
Figure 4-12: Autophagy inhibition mimics wound repair impairment by tunicamycin 
(a) HT-29 cells received bafilomycin A1 (BafA, 5 nM) and rhIL-22 (100 ng/ml) 24 h before 
wounding. PBS or DMSO, respectively, served as stimulation controls, n=18 each. Relative 
wound closure was assessed 24 hours after scratch. (b) Supernatants collected from (a) 24 
h after wounding were analysed for hIL-8 levels via ELISA (n=3 each). Data are shown as 
mean ± s.e.m. and were tested for statistical significance using unpaired Student’s t-test.  
** p<0.01. 
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4.4 IL-22 induces an inflammatory phenotype in Xbp1 and 
Atg16l1 organoids 
IBD risk genes ATG16L1 and XBP1 are linked with unresolved ER stress and 
malfunctioning autophagic machinery (160, 161). To analyse how these risk genes 
coordinate IL-22 function, I used mice with conditional knockout of Atg16l1 or Xbp1 in 
the intestinal epithelium (Atg16l1ΔIEC, Xbp1ΔIEC). IL-22 led to marked UPR activation 
in IL-22 treated compared to control Xbp1ΔIEC mice (figure 4-13). Moreover, Xbp1-
deficient organoids displayed baseline increased expression levels of Cxcl1, the 
murine homologue of human IL-8. After IL-22 administration, Cxcl1 expression 
significantly increased in Xbp1ΔIEC organoids but not in Xbp1 wild type organoids. 
Hence, IL-22 induces a pro-inflammatory program in Xbp1-deficient organoids. 
 
Figure 4-13: IL-22 induces a pro-inflammatory program in Xbp1ΔIEC organoids 
Organoids derived from Xbp1ΔIEC and Xbp1fl mice were treated with either PBS or IL-22 (100 
ng/ml) for 24 h (n=3 each). Expression levels of Cxcl1, sXbp1 and Xbp1 were analysed by 
SYBR green qPCR and normalised to Gapdh. Data are shown as mean ± s.e.m. and 
statistical analysis was performed with unpaired Student´s t-test. * p<0.05, *** p<0.001. 
Since I found that autophagy induction was linked with UPR activation (chapter 4.3), I 
investigated the role of epithelial Atg16l1 after IL-22 stimulation. Similar to the results 
in Xbp1ΔIEC mice, IL-22 potentiated expression of pro-inflammatory cytokines like 
Cxcl1 and Tnf in Atg16l1ΔIEC mice-derived organoids (figure 4-14). Furthermore, IL-22 
induced ER stress markers like sXbp1, thus confirming the previously described 
interplay of autophagy and ER stress. Taken together, IL-22 skews intestinal 
epithelial cells deficient in Atg16l1 to a pro-inflammatory state.  
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Figure 4-14: IL-22 drives a pro-inflammatory signature in Atg16l1ΔIEC organoids 
Organoids derived from Atg16l1ΔIEC and Atg16l1fl mice were treated with either PBS or IL-22 
(100 ng/ml) for 24 h (n=3 each). Expression levels of Tnf, Cxcl1, sXbp1 and Atg16l1 were 
measured by SYBR green qPCR and normalised to Gapdh. Data are shown as mean ± 
s.e.m. and statistical analysis was performed with unpaired Student´s t-test. * p<0.05,  
** p<0.01, *** p<0.001. 
Cellular death of intestinal epithelial cells results in defective barrier function of the 
mucosa, one of the hallmarks of intestinal inflammation. To test whether IL-22-
dependent ER stress affected epithelial cell death, I administered IL-22 to Atg16l1-
deficient organoids. Afterwards, I subjected organoids to a PI-based cell death assay. 
Indeed, IL-22 significantly induced cell death in Atg16l1ΔIEC organoids but not in their 
genotype controls in a dose-dependent manner (figure 4-15).  
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Figure 4-15: IL-22 induces cell death in a state of disordered autophagy 
Organoids derived Atg16l1ΔIEC and Atg16l1fl mice were treated with either PBS or rmIL-22 (1, 
10 or 100 ng/ml) for 24 h (n=3 each). Organoids were subjected to PI staining and 
fluorescence intensities were analysed using flow cytometry. (a) Representative FACS plots 
of dissociated organoid cells derived from Atg16l1ΔIEC and Atg16l1fl mice and treated with IL-
22 (100 ng/ml). (b) Merged images (bright field vs. RFP-filter for PI) from representative 
organoids incubated with PI (1:1,000 solution in medium) for 24h, 100x magnification, bars 
indicate 200 µm. (c) Statistical analysis of % change dead cells. Data are shown as mean ± 
s.e.m. and statistical analysis was performed with unpaired Student´s t-test. ** p<0.01. 
To further determine whether cell death induction is specific for IL-22, I treated 
Atg16l1ΔIEC organoids with the structurally similar IL-10. Interestingly, Atg16l1-
deficient organoid cells underwent cellular death to a smaller extent (figure 4-16). 
Challenge with tunicamycin served as a control. Fitting to the aforementioned 
inhibitory role of autophagy on ER stress, Atg16l1-deficient organoids underwent 
significantly more cellular death upon ER stress induction as with tunicamycin 
challenge.  
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Figure 4-16: IL-10 is not protective in Atg16l1 deficiency 
Organoids derived from Atg16l1ΔIEC and Atg16l1fl mice were treated with either PBS, rmIL-10 
(100 ng/ml), rmIL-22 (100 ng/ml) or tunicamycin (500 ng/ml) for 24 h (n=3 each). Organoids 
were subjected to PI staining and fluorescence intensities were analysed using flow 
cytometry. Data are shown as mean ± s.e.m. and statistical analysis was performed with 
unpaired Student´s t-test. ** p<0.01, *** p<0.001. 
Thus, Atg16l1 and Xbp1 critically control inflammatory signals in the intestinal 
epithelium upon IL-22, preventing excessive epithelial cell death. Loss of Atg16l1 
reverts tissue protection by IL-10.  
4.5 ATG16L1 controls IL-22-depedent STING activation and 
subsequent ISG induction  
To delineate the transcriptional program driven by IL-22 in absence or presence of 
adequate autophagy, Dr. Raheleh Sheibani-Tezerji kindly performed RNA 
sequencing of small intestinal organoids derived from Atg16l1ΔIEC mice or genotype 
controls treated with rmIL-22 for 24 h. In total, I found 2908 differentially expressed 
genes (DEGs) in IL-22 treated organoids. IL-22 up-regulated 586 unique genes in  
Atg161fl/fl and 484 in Atg16l1ΔIEC organoids while IL-22 uniquely down-regulated 794  
genes in Atg16l1fl/fl and 490 genes inAtg16l1ΔIEC organoids (figure 4-17).  
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Figure 4-17: Atg16l1 orchestrates an IL-22-driven type I interferon expression 
signature in intestinal organoids  
(a) Venn diagram showing overall (top, black) differentially expressed genes and significantly 
down-regulated (middle, blue) and up-regulated (below, red) genes in Atg16l1fl and 
Atg16l1ΔIEC in response to stimulation with IL-22 (10 ng/ml), n=4 each. (b) Heat map showing 
clustering of top 20 genes differentially expressed in response to IL-22 (10 ng/ml) according 
to genotype. (c) enriched GO terms of top 250 uniquely upregulated genes in IL-22 treated 
Atg16l1ΔIEC intestinal organoids. (d) STRING-based network analysis of all genes contributing 
to the GO term “innate immune response” detected in (c). All analyses of this figure were 
kindly performed by Dr. Raheleh Sheibani-Tezerji. 
To provide a first functional annotation, a gene set enrichment analysis using the 
gene ontology (GO) term algorithm was performed. Furthermore, DEGs were 
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clustered using network analysis base on the Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING) (200). Surprisingly, only IL-22 treated 
organoids which were deficient for Atg16l1 showed significant enrichment of genes 
involved in type I interferon signalling and response (see figure 4-17d). These results 
imply a strong induction of interferon stimulated genes (ISG) by IL-22 in Atg16l1ΔIEC 
organoids. To confirm these findings, I treated Atg16l1fl and Atg16l1ΔIEC organoids 
with IL-22 (100 ng/ml) for 24 h. I then analysed gene expression of Ifit1 and Ifit3, 
which are well-established representatives for ISG (203). Atg16l1ΔIEC organoids 
displayed increased ISG expression at baseline condition. While administration of IL-
22 moderately induced the analysed genes in Atg16l1fl organoids, strong induction 
was observed in Atg16l1ΔIEC tissue (figure 4-18). These data validate the RNA 
sequencing results, which pointed to a strong ISG induction by IL-22 in Atg16l1ΔIEC 
organoids.  
 
Figure 4-18: Enhanced ISG induction by IL-22 in Atg16l1-deficient organoids 
Organoids derived from Atg16l1ΔIEC and Atg16l1fl mice were treated with either PBS or IL-22 
(100 ng/ml) for 24 h (n=3 each). Expression levels of Ifit1 and Ifit3 were measured by SYBR 
green qPCR and normalised to Gapdh. Data are shown as mean ± s.e.m. and statistical 
analysis was performed with unpaired Student´s t-test. ** p<0.01, *** p<0.001. 
Next, we aimed to delineate the molecular origin of increased IFN-I signature in 
Atg16l1 deficient organoids. Therefore, I tested whether IL-22-mediated ISG 
induction depended on canonical IFN-I inducing signalling cascades like 
cGAS/STING/TBK1 or the RIG-I/MDA5/MAVS axis. I treated organoids derived from 
Atg16l1fl, Atg16l1ΔIEC, Mda5-/- and Tmem173gt mice (mice harbouring a golden ticket 
mutation leading to dysfunction of STING) were treated with IL-22 (1, 10 and 100 
ng/ml) for 24 h and analysed gene expression of Ifit1 and Ifit3. In line with results 
discussed earlier, increased Atg16l1-deficient organoids showed higher ISG 
induction (figure 4-19a). In Tmem173gt organoids, expression of ISG was completely 
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blunted, whereas deficiency of Mda5 did not affect ISG induction upon IL-22 
treatment. To further elucidate the STING-dependent signals upon IL-22, protein 
lysates were generated from IL-22 treated Atg16l1ΔIEC organoids. IL-22 increased 
TBK1 phosphorylation in Atg16l1ΔIEC organoids as revealed by immunoblot analysis 
(figure 4-19b). To validate these findings in another cellular system, I treated Caco-2 
cells deficient for ATG16L1 with IL-22 (100 ng/ml) for 24, 48 and 72h (figure 4-20c). 
Again, TBK1 was phosphorylated in IL-22-treated cells deficient for ATG16L1. In 
conclusion, Atg16l1 deficiency intensifies IL-22-dependent activation of STING 
signalling.  
 
Figure 4-19: STING regulates induction of ISG by IL-22 signals 
(a) Organoids derived from Atg16l1fl, Atg16l1ΔIEC, Mda5-/- and Tmem173-/- mice were treated 
with either PBS or IL-22 (1, 10 or 100 ng/ml) for 24 h (n=3 each). Gene expression level of 
Ifit1 and Ifit3 was measured by SYBR green qPCR and normalised to Gapdh. Data are 
shown as mean ± s.e.m. and statistical analysis was performed with unpaired Student´s t-
test. ** p<0.01, *** p<0.001. (b) Organoids derived from Atg16l1fl and Atg16l1ΔIEC mice were 
treated with either PBS or IL-22 (100 ng/ml) for 24 h. Proteins were extracted, immunoblotted 
and analysed for pTBK1, TBK1 and ATG16L1. GAPDH served as a loading control. (c) 
ATG16L1+/+ and ATG16L1-/- Caco-2 cells were treated with IL-22 (100 ng/ml) for the 
indicated time. Proteins were extracted, immunoblotted and analysed for pTBK1, TBK1 and 
ATG16L1. GAPDH served as a loading control. One representative immunoblot out of two 
independent experiments is shown.  
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Based on the previous finding of STING activation in Atg16l1 deficiency, I 
hypothesised that cytosolic dsDNA was involved in IL-22-dependent ISG induction in 
Atg16l1 deficiency. Using CRISPR/Cas9 technology, Caco-2 cells (a human intestinal 
carcinoma cell line) deficient for ATG16L1 were generated and stimulated with IL-22 
(100 ng/ml) for 24 h. I then performed immunofluorescence staining against dsDNA. 
Indeed, ATG16L1-/- deficiency in Caco-2 cells led to accumulation of 
cytosolic/extranuclear dsDNA which was further induced by IL-22 stimulation (figure 
4-20, analysis kindly performed by Dr. Kareen Bartsch).     
  
Figure 4-20: IL-22 releases cytosolic dsDNA in ATG16L1 deficiency 
(a) Caco-2 cells proficient (ATG16L1+/+) or deficient (ATG16L1-/-) for ATG16L1 were treated 
with either PBS or IL-22 (100 ng/ml) for 24 h (n=3 each) before fixation and 
immunofluorescence staining against dsDNA. White arrows indicate extranuclear dsDNA 
punctae.  White bars indicate 10 µm.  (b) Quantification of cells positive for cytoplasmic 
dsDNA. Data are shown as mean ± s.e.m. and statistical analysis was performed with 
unpaired Student´s t-test. * p<0.05. The analysis was kindly performed by Dr. Kareen 
Bartsch. 
To exclude that upregulation of STING signalling was due to increased availability of 
STING protein or altered post-translational modification or impaired cellular 
trafficking, Atg16l1fl and Atg16l1ΔIEC organoids were generated and treated with IL-22 
(1, 10 or 100 ng/ml) for 24 h. IL-22 dose-dependently induced gene expression of 
Tmem173, which encodes for STING (figure 4-21), an effect not affected by Atg16l1 
status. In line with this, immunoblot analysis revealed an undistinguishable IL-22-
dependent induction of STING in Atg16l1ΔIEC mice compared to the wild-type control. 
Stimulation with hydroxyurea, a DNA double strand break-inducing agent, served as 
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a control. Thus, STING is not regulated by Atg16l1 on transcript and total protein 
level.  
 
Figure 4-21: Induction of Tmem173/STING by IL-22 is not altered in Atg16l1-deficient 
organoids 
(a) Organoids derived from Atg16l1ΔIEC and Atg16l1fl mice were treated with either PBS or IL-
22 (1, 10 or 100 ng/ml) for 24 h (n=3 each). Gene expression level of Tmem173 was 
measured by SYBR® green qPCR and normalised to Gapdh. Data are shown as mean ± 
s.e.m. and statistical analysis was performed with unpaired Student´s t-test. *** p<0.001. (b) 
Organoids derived from Atg16l1ΔIEC and Atg16l1fl mice were treated with either PBS, IL-22 
(100 ng/ml) or hydroxyurea (HU, 1 μM) for 24 h. Proteins were extracted, immunoblotted and 
analysed for STING expression. GAPDH served as a loading control. One representative 
immunoblot out of two independent experiments is shown. 
To investigate whether control of ISG induction by Atg16l1 relied on canonical 
autophagy, I treated Atg16l1fl organoids with IL-22 (100 ng/ml) for 24h along with 
bafilomycin A1 (BafA, 5nM), a late phase autophagy inhibitor which blocks fusion of 
autophagosomes with lysosomes. Bafilomycin co-treatment of organoids mimicked 
the effect of Atg16l1 deletion on ISG induction as shown by induction of Ifit1 and Ifit3 
expression after IL-22 stimulation (figure 4-22). This finding suggests autophagy 
dysfunction as a result of Atg16l1 deletion responsible for uncontrolled ISG induction. 
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Figure 4-22: Bafilomycin treatment mimics Atg16l1ΔIEC phenotype of potentiation of IL-
22-dependent ISG expression 
Organoids derived from small intestine of wild type mice were treated with IL-22 (100 ng/ml) 
and bafilomycin A1 (BafA, 5nM) for 24 h, n=3 each. PBS or DMSO served as stimulation 
controls, respectively. Expression levels of Ifit1 and Ifit3 were analysed by SYBR green 
qPCR and normalised to Gapdh expression. Data are shown as mean ± s.e.m. and were 
tested for statistical significance using unpaired Student’s t-test. * p<0.05, ** p<0.01,  
*** p<0.001. 
The WD40 repeat domain of the ATG16L1 protein is believed to form a platform 
without enzymatic activity for protein-protein interactions, as it is thought to fold into 
β-propellers. Truncated variants of ATG16L1 lacking the WD40 repeat domain 
displayed impaired autophagy function and was associated with cellular phenotypes 
in mice reminiscing Atg16l1 knockouts (166). Similarly, the protein encoded by the 
common IBD risk variant ATG16L1T300A  is cleaved by caspase-3 at the stalk of the 
WD40 domain, ultimately resulting in loss of functional ATG16L1 protein (204). To 
test whether ATG16L1-dependent control of ISG induction was affected by absence 
of WD40 repeat domain, small intestinal organoids were generated from mice 
ubiquitously harbouring the WD40 truncated variant of ATG16L1 (Atg16l1ΔWD40) and 
analysed for ISG expression after challenge with IL-22 (100 ng/ml) for 24 h. 
Expression levels of Cxcl10, Ifit1 and Ifit3 showed slight, albeit not significant 
reduction in response to  IL-22, implying a non-essential role of the WD40 repeat 
domain in controlling ISG induction (figure 4-23).  
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Figure 4-23: Absence of the WD40 repeat domain in ATG16L1 did not alter induction of 
ISG by IL-22 
Organoids derived from Atg16l1ΔWD40 and Atg16l1wt mice were treated with either PBS or IL-
22 (100 ng/ml) for 24 h (n=3 each). Expression levels of Ifit1, Ifit3 and Cxcl10 were measured 
by SYBR® green qPCR and normalised to Gapdh. Data are shown as mean ± s.e.m. and 
statistical analysis was performed with unpaired Student´s t-test. *** p<0.001. 
Taken together, ATG16L1 controls ISG induction by IL-22, an effect dependent on 
the cGAS/STING/TBK1 pathway. This role of ATG16L1 depends on the autophagy 
supporting properties of the protein but not on the WD40 repeat domain.  
4.6 IL-22 and downstream type I interferons synergistically 
induce TNFα-dependent necroptosis 
Having shown that IL-22 induces a type I interferon response in a STING-dependent 
fashion particularly in absence of Atg16l1, I unravelled the role of this signalling on 
cell death and mucosa inflammation. Gene expression analysis of intestinal 
organoids for Tnf and Cxcl1 revealed strong upregulation of these NF-κB target 
genes in absence of Atg16l1, which was potentiated by IL-22 administration (figure 4-
14). On the flipside, Tmem173 repressed Tnf induction by IL-22 while Cxcl1 gene 
expression was unaffected (figure 4-24). Importantly, IL-22-dependent induction of 
ISG was completely abolished in Tmem173 knockout organoids. These findings 
indicate a type I interferon-dependent regulation of epithelial Tnf expression, with 
STING signalling enhancing IL-22-dependent Tnf induction.  
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Figure 4-24: Tnf expression is dependent on STING-signalling 
Organoids derived from wild type and Tmem173gt mice were treated with IL-22 (100 ng/ml) 
for 24 h (n=3 each). Expression levels of Cxcl1 and Tnf were measured by SYBR® green 
qPCR and normalised to Gapdh. Data are shown as mean ± s.e.m. and statistical analysis 
was performed with unpaired Student´s t-test. ** p<0.01, *** p<0.001 
To further investigate the role of type I interferons in Tnf induction, organoids 
harbouring a defective Tmem173 variant (golden ticket mutation) were generated and 
treated with IL-22 and IFN-β. Strikingly, IL-22 and IFN-β synergistically induced Tnf in 
Tmem173gt (figure 4-25, stimulation kindly performed by Dr. Go Ito).  
 
Figure 4-25: IL-22 and type I interferons synergistically induce Tnf 
Organoids derived from Tmem173gt mice and their genotype controls were treated with rmIL-
22 and rmIFN-β (100 ng/ml each) for 24 h (n=3 each). Expression levels of Cxcl1 and Tnf 
were measured by SYBR® green qPCR and normalised to Gapdh. Data are shown as mean 
± s.e.m. and statistical analysis was performed with unpaired Student´s t-test. *** p<0.001. 
Stimulation kindly performed by Dr. Go Ito.  
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Having established that type I interferons act as signal enhancer for IL-22-dependent 
induction of Tnf, I investigated the role of epithelial tumor necrosis factor alpha 
(TNFα). TNFα is a cell death inducing cytokine, while the modus of cell death 
context-dependently varies between apoptosis via canonical membrane-bound death 
receptors like FADD and necroptosis in a RIPK1, RIPK3 and MLKL1-dependent 
fashion (205) (206). Necroptosis is of particular interest as it has been implicated in 
pathogenesis of IBD (91, 207).  
To test whether necroptosis was a relevant cell death mode in the context of IL-22 in 
autophagy deficiency, intestinal organoids were generated from Ripk3 knockout 
(Ripk3-/-) mice, from mice having a mutated variant of Ripk1 with a loss of function of 
the kinase domain (Ripk1D138N) (205) and from Mlkl knockout (Mlkl-/-) mice. 
Administration of IL-22 and bafilomycin induced significant cell death in organoids of 
each genotypes, but Mlkl-/- organoids were significantly protected from cellular death 
while Ripk3-/- organoids behaved similar to the wild type (figure 4-26). Organoids 
derived from Ripk1D138N mice were albeit slightly protected from BafA + IL-22-induced 
cellular death. 
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Figure 4-26: ISG induction by IL-22 and defective autophagy induces necroptosis 
Organoids derived from Ripk3-/-, Ripk1D138N and Mlkl-/- mice and their genotype controls were 
treated with rmIL-22 (100 ng/ml) and BafA (5 nM) for 24 h (n=3 each). (a) Merged images 
(bright field vs. RFP-filter for PI) from representative organoids incubated with PI (1:1,000 
solution in medium) for 24h, 100x magnification, bars indicate 200 µm. (b) Organoids were 
subjected to PI and fluorescence intensities were quantified using flow cytometry. (c) 
Statistical analysis of PI+ cells from (b). Data are shown as mean ± s.e.m. and statistical 
analysis was performed with unpaired Student´s t-test. *** p<0.001.  
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Based on these data, I hypothesised that excessive STING signalling contributes to 
necroptotic cell death in autophagy deficient epithelial cells, via IFN-I-dependent 
downstream engagement of TNFα. To test this, I stimulated Tmem173gt and wild type 
organoids with IL-22 and BafA. As presumed, Tmem173gt organoids succumbed less 
after IL-22+BafA challenge compared to the wild type controls (figure 4-27).  
 
Figure 4-27: Loss of STING protects against IL-22 induced necroptosis 
Organoids derived from Tmem173gt mice and their genotype controls were treated with rmIL-
22 (100 ng/ml) and BafA (5 nM) for 24 h (n=3 each). Organoids were subjected to PI and 
fluorescence intensities were quantified using flow cytometry. (a) representative FACS plots. 
(b) Statistical analysis of PI+ cells. (c) Merged images (bright field vs. RFP-filter for PI) from 
representative organoids incubated with PI (1:1,000 solution in medium) for 24 h, 100x 
magnification, bars indicate 200 µm.. Data are shown as mean ± s.e.m. and statistical 
analysis was performed with unpaired Student´s t-test. *** p<0.001.  
Hence, RIPK1/RIPK3-independent necroptosis is a critical mode of cell death 
resulting from signalling via the IL-22/STING/ISG/TNFα axis. 
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4.7 IL-22 drives a local, small intestinal inflammatory 
phenotype in the absence of epithelial Atg16l1 and Xbp1 
I have shown that absence of Xbp1 or Atg16l1 renders IL-22 receptive intestinal 
organoids to a more cell death prone phenotype. I therefore meant to investigate 
whether the failed epithelial interplay contributes to the manifestation of small 
intestinal inflammation in mice or not. 
To further confirm a biologically meaningful pro-inflammatory role of IL-22 in the 
context of epithelial  Atg16l1 deficiency, Atg16l1ΔIEC and Atg16l1fl/fl mice were treated 
with either 2 µg IL-22 or PBS via intraperitoneal injection for 6 consecutive days 
(figure 4-28a). Colitis was induced by 2% DSS in drinking water from day 2 until days 
6 of the IL-22 treatment. Daily assessment of body weight change revealed 
significant weight loss in the group of IL-22-treated Atg16l1ΔIEC mice, which was 
accompanied by significant increase of the Disease Activity Index score (figure 4-
28b, composed of weight loss, stool consistency and rectal bleeding). However, liver, 
spleen and caecum weight, markers for systemic inflammatory burden, were similar 
in both genotypes (figure 4-28c). 
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Figure 4-28: Assessment of the disease course of Atg16l1ΔIEC mice after 6 days of IL-22 
treatment 
(a) Treatment scheme of IL-22 administration and DSS challenge. (b) Body weight relative to 
day 0 value of Atg16l1ΔIEC and Atg16l1fl mice treated with either PBS or IL-22 (2 µg) i.p. every 
day for 6 days (n=5 each). 2% DSS were administrated from day 2 until day 6. Disease 
Activity Index at day 6 is shown in a separate plot. (c) Assessment of spleen, liver and 
caecum weight relative to bodyweight. Data are shown as mean ± s.e.m. and statistical 
analysis was performed with nonparametric Mann-Whitney U test. * p<0.05, ** p<0.01. 
Next, intestinal inflammation levels were investigated by histological assessment. 
H&E staining revealed slightly elevated inflammation scores in the ileal mucosa of 
Atg16l1ΔIEC mice compared to their wild-type controls which increased significantly 
upon IL-22 treatment (figure 4-29). To evaluate epithelial cell death in the mucosa, I 
performed TUNEL staining. TUNEL+ cells accumulated in epithelial crypts of 
Atg16l1ΔIEC mice but not in Atg16l1fl mice. IL-22 treatment had no effect on TUNEL+ 
cell number in Atg16l1fl mice but increased number of dead epithelial cells in absence 
of Atg16l1. In line with this, γH2AX+ cells were also enriched in Atg16l1ΔIEC small 
intestinal crypts, especially with IL-22 treatment, underscoring the hypothesis of DNA 
damage accumulation in autophagy-deficient conditions. This finding was 
underpinned by accumulation of pTBK1+ punctae in the crypts of IL-22-treated 
Atg16l1ΔIEC mice but not of Atg16l1fl mice, suggesting activation of the 
cGAS/STING/pTBK1 pathway downstream of DNA damage.  
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Figure 4-29: Histological assessment of small intestinal tissue of Atg16l1ΔIEC mice 
treated with IL-22 and 2% DSS 
Histological assessment of ileal tissue obtained from the experiment of figure 4-28. H&E 
staining including assessment of ileal inflammation score as well as TUNEL, anti-γH2AX IHC 
and anti-pTBK1 (2nd antibody: anti-rabbit Alexa Fluor 555, red) / anti-E-cadherin (2nd 
antibody: anti-mouse Alexa Fluor 488, green) / DAPI (blue) IF staining were performed 
(colour code as in figure 4-28). White bars indicate 100 µm. Data are shown as mean ± 
s.e.m. and statistical analysis was performed using nonparametric Mann-Whitney U  test. * 
p<0.05, ** p<0.01, *** p<0.001. 
Next, small intestinal crypts from the same experiment were collected and mRNA 
was isolated for gene expression analysis. In line with results from ex vivo organoid 
cultures, solely crypts derived from IL-22-treated Atg16l1ΔIEC mice displayed an 
increased type I interferon (IFN-I) signature, ultimately resulting in Tnf expression 
(figure 4-30).  
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Figure 4-30: IFN-I signature in small intestinal crypts derived from Atg16l1ΔIEC mice 
treated with IL-22 and 2% DSS 
Gene expression analysis of small intestinal crypts obtained from the mice used in the 
experiment of figure 4-28. Expression levels of Cxcl10, Ifit1, Ifit3 and Tnf were measured by 
SYBR® green qPCR and normalised to Actb. Data are shown as mean ± s.e.m. and 
statistical analysis was performed using nonparametric Mann-Whitney test. * p<0.05,  
** p<0.01. 
These results validated the role of IFN-I in IL-22-induced cell death in highly 
proliferating epithelial cells deficient for Atg16l1. To integrate the previous established 
role of ER stress resolution in IL-22 biology, Atg16l1ΔIEC/Xbp1ΔIEC mice at the age of 
8-10 weeks were subjected to i.p. rmIL-22 treatment for 13 days every other day 
before sacrifice (figure 4-31a, in vivo treatment and sacrifice kindly performed by 
Dr. Markus Tschurtschenthaler and Dr. Joya Bhattacharyya, Cambridge). This 
age was chosen as Atg16l1ΔIEC/Xbp1ΔIEC mice develop spontaneous inflammation at 
the age of 8 to 12 weeks. H&E staining revealed spontaneous transmural ileal 
inflammation in Atg16l1ΔIEC/Xbp1ΔIEC mice in line with previous reports (208). 
Administration of IL-22 aggravated spontaneous inflammation in Atg16l1ΔIEC/Xbp1ΔIEC 
mice but not wild type controls, an effect predominantly localised in crypts (figure 4-
31b). This was accompanied by increased focal anti-γH2AX staining and 
extranuclear anti-dsDNA punctae, indicating an accumulation of extranuclear 
damaged DNA in the epithelial crypts of Atg16l1ΔIEC/Xbp1ΔIEC mice especially after IL-
22 treatment (figure 4-31c). In line with finding from my organoid model, IL-22 
induced accumulation of pTBK1 in absence of epithelial Xbp1 and Atg16l1 in vivo.  
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Figure 4-31: IL-22 exacerbates spontaneous ileal inflammation in Atg16l1ΔIEC/Xbp1ΔIEC 
mice 
(a) Treatment scheme of IL-22 i.p. injections over the course of 13 days. (b) Histological 
assessment of ileal tissues from the experiment in (a). H&E staining and assessment of ileal 
inflammation score, TUNEL staining and statistical analysis of TUNEL+ cells. Anti-γH2AX 
immunohistochemistry staining and statistical analysis of γH2AX+ cells. (c) Anti-dsDNA (2nd 
antibody: anti-mouse Alexa Fluor 488, green) / DAPI (blue) and anti-pTBK1 (2nd antibody: 
anti-rabbit Alexa Fluor 555, red) / anti-E-cadherin (2nd antibody: anti-mouse Alexa Fluor 488, 
green) / DAPI (blue) immunofluorescence staining with the statistical analyses of pTBK1+ and 
dsDNA+ punctae (white arrow indicate dsDNA+ punctae) per crypt. White bars indicate 100 
µm. Data are shown as mean ± s.e.m. and statistical analysis was performed using 
tnonparametric Mann-Whitney U test. * p<0.05, ** p<0.01, *** p<0.001. 
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I have shown that systemic IL-22 treatment renders aggravated small intestinal 
inflammation in Atg16l1ΔIEC and Atg16l1ΔIEC/Xbp1ΔIEC mice. We further delineated in 
in vitro experiments that excessive STING/IFN-I contributes to cell death phenotype 
in Atg16l1ΔIEC organoids. We therefore postulated that IL-22-dependent exacerbation 
of small intestinal cell death and inflammation depends on IFN-I signalling. To test 
this I conducted another in vivo colitis study using Atg16l1ΔIEC mice including an 
additionally treatment group which received neutralising antibodies that block the 
common downstream receptor interferon-α/β-receptor (IFNAR). Mice were treated 
with 2% DSS for the first 5 days of 10 days i.p. treatment with IL-22. Anti-IFNAR 
antibodies were administrated on day 0, 2, 4 and 6 (figure 4-32a), which partially 
reverted ileal inflammation on histological level in Atg16l1ΔIEC mice challenged with 
IL-22, reflected by a significant lower histology score and significantly fewer TUNEL+ 
cells (figure 4-32b).  
 
Figure 4-32: Histological assessment of small intestinal tissue of Atg16l1ΔIEC mice 
treated with IL-22, anti-IFNAR ab and 2% DSS 
(a) Treatment scheme of experimental colitis with 2% DSS, IL-22 i.p. injections and anti-
IFNAR ab treatment over the course of 10 days. (b) H&E staining and assessment of ileal 
inflammation score, as well as TUNEL staining and statistical analysis of TUNEL+ cells. 
White bars indicate 100 µm. Data are shown as mean ± s.e.m. and statistical analysis was 
performed using nonparametric Mann-Whitney U test. * p<0.05, *** p<0.001. 
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This suggests a pro-inflammatory role for IFN-I in the small intestine as downstream 
effectors of IL-22. As chronic inflammation in human IBD often affects colonic sites, 
especially in UC, I analysed colonic tissues obtained from the above-mentioned 
animal experiment for inflammatory phenotypes. Atg16l1ΔIEC mice displayed a higher 
histological level of inflammation compared to their wild type controls. However, this 
was not affected by IL-22 administration (figure 4-33). Additional neutralisation of 
IFNAR did not rescue the genotype-dependent inflammatory phenotype in 
Atg16l1ΔIEC mice. Therefore, the IL-22/STING/IFN-I axis is not critical for colonic 
mucosal homeostasis. 
 
Figure 4-33: Histological assessment of colonic tissue of Atg16l1ΔIEC mice treated with 
IL-22, anti-IFNAR ab and 2% DSS 
H&E staining and assessment of colonic inflammation score from samples obtained from the 
experiment in figure 4-32. White bars indicate 500 µm or 200 µm, respectively. Data are 
shown as mean ± s.e.m. and statistical analysis was performed using nonparametric Mann-
Whitney U test. * p<0.05. 
In sum, these results establish a key role of Atg16l1 and Xbp1 in coordinating the 
dignity of IL-22 in the context of intestinal inflammation in vivo. 
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5 Discussion 
In this study, I demonstrated that two IBD risk genes ATG16L1 and XBP1, 
representing fundamental disease pathomechanisms autophagy and ER stress, 
direct the dignity of IL-22 exposure of the intestinal epithelium. In in vitro models, I 
showed that IL-22 surprisingly induced ER stress, which counters the initial 
hypothesis of an ER stress-ameliorating role of the IL-10 superfamily based on prior 
studies (162, 163). Furthermore, my results pointed towards a detrimental role of IL-
22 in the context of Atg16l1 deficiency, namely by necroptosis induction. Using a 
systemic approach, I identified the type I interferon axis as one of the distinct critical 
molecular signals in Atg16l1 deficiency. Next, the cGAS/STING system was 
pinpointed down to facilitate IFN-I signals in response to cytosolic dsDNA after IL-22 
treatment in our model. I discovered that IL-22 and IFN-I synergistically promote 
necroptosis. Lastly, I confirmed the in vitro results in vivo by demonstrating 
aggravated cell death and widespread ileal inflammation in Atg16l1ΔIEC and 
Atg16l1ΔIEC/Xbp1ΔIEC mice treated with IL-22, which was rescued by additional 
blocking of IFN-I signalling.  
This work demonstrates a surprising link between pathophysiological principles of 
intestinal inflammation. As chronically impaired states of ER stress, autophagy and 
IL-22 have been implicated in a variety of human disorders including metabolic 
syndrome and cancer, the study has important consequences for a broad spectrum 
of human diseases beyond IBD. IL-22 plays as an essential role in orchestrating 
intestinal homeostasis. It is secreted from circulating immune cells and acts on 
intestinal epithelial cells to mount effective regenerative as well as antibacterial and 
antiviral cellular programs. With IL-22 currently under development by several 
companies in such indications (prominently by Genentech as IL-22Fc in IBD, 
metabolic syndrome and skin ulcer disease) the novel dichotomy of IL-22 biology 
shown in this thesis may have profound clinical implications. The critical findings of 
this work are as followed and addressed in this chapter: 
(i) Proficient autophagy and ER stress resolution are critical prerequisites for IL-
22 induced epithelial regeneration 
(ii) IL-22 is an inducer of the cGAS/STING/IFN-I signalling loop, a process 
controlled by ATG16L1 and XBP1 
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(iii) Excessive IL-22-dependent STING activation due to deletion of Atg16l1 and 
Xbp1 results in necroptotic cell death via TNFα induction 
5.1 Friend or foe? Exploring the dark side of IL-22 
IL-22 is a pleiotropic cytokine, which exerts an important protective role on epithelial 
homeostasis by controlling proliferative capacity, but also acts on antimicrobial and 
antiviral gene expression (209). However, it has been shown that under certain 
conditions unrestrained IL-22 signalling may evoke tissue damage (210), impeding 
epithelial expansion in vitro (98) and may thus aggravate inflammatory responses 
(211).  
5.1.1 IL-22/STAT3 induces ER stress 
In this study, IL-22 indeed increased ER stress levels in both chemical (by 
tunicamycin, figures 4-1 to 4-3) and genetic (Atg16l1ΔIEC, Xbp1ΔIEC, figures 4-13 & 4-
14) setting and thereby impeded epithelial regeneration as demonstrated by wound 
healing assays (figure 4-8). This was associated with increased expression of pro-
inflammatory cytokines (figure 4-8). In a murine model of diminished mucosal IL-22 
expression (Il23rΔIEC), ER stress markers were inversely decreased (figure 4-4). 
Impaired autophagy led to uncontrolled UPR induction upon ER stress and therefore 
autophagy blockade mimicked the described phenomena of IL-22 (figure 4-12). Vice 
versa induction of autophagy by rapamycin dampened IL-22-dependent ER stress 
and reverted the inflammatory, anti-regenerative phenotype (figures 4-9 & 4-10). 
Interestingly, STAT3 activation was required for ER stress induction as chemical 
inhibition of STAT3 also repressed UPR induction and improved wound healing of IL-
22 and tunicamycin challenged in vitro scratch wounds (figures 4-9 & 4-10). These 
findings evoked two hypotheses: First, secretory burden and replication pressure are 
the main drivers of IL-22 promoted ER stress as expression of antimicrobial peptides 
and cellular replication has been shown to be STAT3-dependent (56). Second, 
STAT3 is crucial in maintaining homeostasis of autophagy as phosphorylation of 
STAT3 (downstream of IL-22) has been implicated to be both inhibitory and activating 
on the autophagy machinery (165, 212, 213). Imbalanced autophagy homeostasis 
might lead to disinhibited ER stress after IL-22 challenge in the scenario of intestinal 
inflammation, though this aspect was not in this work’s focus. However, STAT3 
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inhibition was not sufficient to repress ER stress-dependent induction of IL-8 (figure 
4-9), one of the most known targets of NF-κB signalling, indicating that STAT3 is 
dispensable for this signalling branch.  
Absence of ER stress and autophagy regulators like Xbp1 or Atg16l1 altered IL-22 
signalling. These conditions exacerbated IL-22-induced pro-inflammatory cytokine 
signatures and signalling, alongside with cellular death induction (figures 4-13 to 4-
15). In line this that, we challenged mice deficient for Atg16l1 and Xbp1 with systemic 
IL-22, leading to aggravated DSS induced (Atg16l1ΔIEC, figure 4-29) or spontaneous 
(Atg16l1ΔIEC/Xbp1ΔIEC, figure 4-31) ileal inflammation as evidenced by accumulation 
of TUNEL+ dead epithelial cells. Interestingly, IL-22 selectively exacerbated small 
intestinal inflammation but not colitis in these settings (figures 4-28 & 4-33), which 
suggested a role for IL-22 in Crohn’s-like phenotypes.  
Importantly, IL-22Fc is under evaluation as a therapeutic drug in IBD due to its pro-
regenerative role in general. This work, however, suggests a careful selection of IBD 
patients before treatment with IL-22Fc as genetic footprints of these patients are 
often associated with increased ER stress and defective autophagy, exemplified by 
the high frequency of the ATG16L1T300A variant (rs2241880) of around 55% in the 
European population (24). Under these circumstances, the results of the ongoing 
phase Ib trial of IL-22Fc in IBD should be carefully evaluated for safety.  
Hence, I revealed novel interdependency between cellular stress characteristic for 
IBD and IL-22 signalling. IL-22 induced a pro-inflammatory signalling that 
synergistically enhanced and was driven by ER stress in intestinal epithelial cells. 
This effect was controlled by autophagy function and downstream STAT3.  Vice 
versa, the outcome of IL-22 signalling in the intestinal epithelium depended on a 
functioning autophagic machinery and proper resolution of ER stress, adding new 
dimensions of so far described dichotomies in IL-22 biology (214).  
5.1.2 Target specificity of the IL-10 superfamily? 
Contrasting the role of IL-10 on epithelial ER stress in goblet cells (162), I did not 
observe induction of ER stress and cellular death in Atg16l1 deficient organoids after 
IL-10 treatment (figure 4-5 & figure 4-16) although the experimental setups were 
identical. This discrepancy can be explained by the different site of inflammation 
(colon vs. small intestine). However, our working group demonstrated that IL-10 
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along with IL-19, another member of the IL-10 superfamily, failed to induce IFN-I 
signature as well as Tnf in colorectal adenocarcinoma cell lines and small intestinal 
organoids (data not shown). Hence, the activation of the STING axis was specific for 
IL-22 within the IL-10 superfamily. Additionally, IL-10 and IL-19 failed to 
phosphorylate STAT3 in equivalent doses to IL-22, underscoring the 
abovementioned role of STAT3 in this context (data not shown). These in vitro 
findings were confirmed in intestinal organoid models, which resemble the in vivo 
epithelium in morphological hallmarks like cellular polarity, crypt-villus architecture, 
cell type differentiation and cellular function (105). The specific can be explained by 
the unique downstream STAT3 of IL-22R1, one subunit of the receptor for IL-22, 
while the other subunit IL-10R2 is shared with other cytokines of the IL-10 
superfamily like IL-10.  
5.2 ATG16L1 and XBP1 orchestrate cGAS/STING-
dependent induction of IFN-I 
5.2.1 IFN-I in chronic inflammatory disease 
Type I interferons (IFN-I) like interferon α (IFNα) or IFNβ are cytokines involved in 
anti-infective defence, in particular in antiviral response, and possess 
immunoregulatory functions like establishing the Th1/Th2 balance. Overall, type I 
interferons possess rather pro-inflammatory properties, which paradoxically are 
protective in specific diseases like viral hepatitis, multiple sclerosis and melanoma. In 
the intestinal epithelium, deletion of a central receptor of IFN-I signalling called 
interferon alpha/beta receptor (IFNAR) caused microbial changes which facilitate 
hyperproliferation of IECs and expansion of the Paneth cell niche (215). Hence, IFN-I 
signalling clearly contributes to the intestinal homeostasis.  
Previous studies already attributed IFN-I as modulators of IL-22 signalling, switching 
the main downstream target from protective STAT3 to pro-inflammatory STAT1 
activation (62). Moreover, ATG16L1 has been linked to IFN-I signalling as ATG16L1-
deficient cells exert RIG-I/melanoma differentiation antigen 5 (MDA5)/mitochondrial 
antiviral-signaling protein (MAVS)- or TRIF-dependent interferon induction (150, 216). 
This was associated with an improved survival in colorectal cancer as IFN-I 
upregulation promotes anti-tumour responses. In this work, we used a systemic 
approach using full mRNA transcriptome sequencing of organoids to determine 
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differentially regulated genes and signals upon IL-22 treatment in defective 
autophagy. Genes involved in innate immunity are amongst the top differentially 
expressed genes, with a big cluster around a type-I interferon signature (see figure 4-
17). Indeed, IL-22 is a potent inducer of IFN-I in IECs as indicated by dose-
dependent upregulation of downstream targets like Ifit1, Ifit3 and Cxcl10 in further in 
vitro experiments (figure 4-19). In line with this, canonical markers for IFN-I signalling 
(Ifit1, Ifit3 and Cxcl10) were found up-regulated in Atg16l1-deficient IECs, particularly 
after IL-22 challenge (figure 4-18 & 4-19). Chemical inhibition of autophagy by 
bafilomycin mimicking this finding (figure 4-22). Interestingly, the WD40 domain was 
dispensable for Atg16l1 to control ISG induction by IL-22 (figure 4-23). Type I 
interferons might therefore play a role in IL-22 driven inflammation in the context of 
autophagy defects. In vivo rescue of DSS-challenged and IL-22-treated Atg16l1ΔIEC 
mice using recombinant antibodies against IFNAR supported this hypothesis (see 
figure 4-32). Together with the previous described findings on epithelial Ifnar (215), 
the increased levels of IFN-I in Atg16l1 deficiency might contribute to the phenotype 
of Atg16l1ΔIEC mice (less and hypomorphic Paneth cells, impaired epithelial 
regeneration) (153). To prove this, generation of Atg16l1ΔIEC/IfnarΔIEC mice is required 
to evaluate the proposed phenotypical rescue. The experiment in figure 4-32, 
however, did not exclude that IFNAR neutralisation ameliorated colitis IL-22-
independently, though epithelial deletion of Ifnar had no effect on colitis severity 
(215). Therefore, another control experiment including anti-IFNAR without IL-22 
administration is necessary.  
Other differentially regulated signalling pathways involve ER related functions and 
signals like response to ER stress and toxic substances, protein N-linked 
glycosylation and phospholipid biosynthetic processes as well as antigen processing 
of endogenous peptides (see figure 4-17).  
5.2.2 Autophagy as a central regulator of STING signalling 
One of the main questions raised from these findings addressed the intracellular 
signalling which linked IL-22 stimulation with IFN-I production. Two canonical 
signalling pathways were found interesting in this scenario: (i) the RIG-I/MDA5/MAVS 
pathway and (ii) the cGAS/STING/TBK1 cascade. Both intracellular systems 
converge in IFN-I production upon sensing of intracellular nucleic acids by RIG-I 
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(ssRNA and dsRNA) and cGAS (dsDNA), respectively. Recently, a newly established 
autophagy/ATG16L1-governed axis involving TLR4/TIR-domain-containing adapter-
inducing interferon-β (TRIF) was found to be a critical contributor of IFN-I response in 
an IBD setting (150).  
STING is the central integrator of cytoplasmic dsDNA mediated immune response 
which has been genetically and mechanistically implicated in anti-infective defence 
(217, 218) and in the pathophysiology of systemic lupus erythematosus (SLE) and 
diseases with lupus-like phenotypes (219). Indeed, excess of dsDNA contribute to 
the development of autoantibodies against dsDNA, one of the hallmarks and 
diagnostic criteria for SLE. Moreover, a few rare conditions like the Aicardi-Goutières 
syndrome associated with accumulation of dsDNA fragments due to massive DNA 
double strand breaks display excessive STING activation, ultimately leading to a type 
I interferonopathy (184) and immunosenescence of tissues (220). The mechanisms 
of STING-dependent IFN-I induction is currently under review as potential target in 
immunotherapy in cancer settings, as several studies infer critical roles of STING in 
coordinating innate immune response (121, 203).  
Human cells harbouring hypomorphic ATG16L1 variants support induction of type I 
interferon response upon dsRNA challenge in a mitochondrial antiviral signalling 
(MAVS)-dependent fashion (216). Similarly, cytosolic dsDNA is an established 
inducer of ISG (115). Proteins involved in autophagy are crucial for removal of 
cytosolic dsDNA as deficiency in several autophagy related genes resulted in 
exacerbated dsDNA-mediated activation of stimulator of interferon genes (STING)-
dependent ISG induction (221). Here, Mda5 knock-out did not affect ISG induction by 
IL-22 whereas Tmem173 depletion in organoids completely diminished ISG induction 
(figure 4-19). Interestingly, IL-22 induces Tmem173/STING to enhance ISG induction 
(figure 4-21), which is in line with results reported in colonic organoids (58). IL-22 
treatment enhanced downstream phosphorylation of TBK1 by STING in Atg16l1-
deficient organoids and epithelial cells in vitro and in vivo. These results point 
towards the cGAS/STING system as the critical link between IL-22 signalling and 
IFN-I production. Another IFN-I activating signalling branch in context of defective 
autophagy has been described for the interdependency of STING and Atg9a in 
fibroblast models (222). To ultimately prove the role of STING in Atg16l1 deficiency, 
the generation of Atg16l1ΔIEC/Tmem173ΔIEC mice to intensively study the signalling in 
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organoids and demonstrate a blunted IFN-I signature would be necessary. 
Surprisingly, the RIG-I/MDA5/MAVS cascade does not play a major role in the 
context of inflammation, contrasting the described ATG16L1T300A-dependent role in 
colorectal cancer (216).  
The excessive increase of cGAS/STING response may be important for either 
removal of active STING signalling-complexes (222) or involved in the generation of 
the endogenous activation principle by aggravating the ER stress-mitochondria axis, 
which in turn leads to the induction of ROS- dependent nuclear DNA damage, as 
described previously (210). Indeed, STING signalling has been linked to ER stress 
and selective autophagy of stressed ER membrane (ER-phagy/reticulophagy) as a 
compensatory mechanism (120). For instance, Prabakaran et al showed that p62-
dependent autophagy restrains overt STING/TBK1/IRF3-dependent IFN-I signals be 
p62-mediated autophagic degradation of STING (223). STING activation also 
promotes a kind of cell death referred to as lysosomal cell death upon translocation 
to lysosomal membrane (224), indicating that trafficking of STING is crucial for 
cellular fate. Impairment of this lysosomal trafficking linked to insufficient autophagy 
might also affect STING signalling under this aspect. In our model, loss of autophagic 
capacity could be causative for uncontrolled STING-dependent ER stress due to 
insufficient degradation of STING. Surprisingly, Xbp1 deficiency led to a completely 
blunted ISG signal upon IL-22 and bafilomycin treatment (data not shown), indicating 
that either XBP1 specifically controls the STING/IFN-I cascade, that STING-
dependent signals wear out under chronic ER stress conditions or that compensatory 
autophagy/reticulophagy lead to degradation of ER resident STING. This autophagy-
STING axis will hence be explored more densely due to new insights into the role of 
selective autophagy in the IBD context. Furthermore, the role of the STING axis is 
under extensive investigation as potential therapeutic target in the context of 
immunotherapy in cancer settings (122, 225). 
dsDNA is the canonical activator of cGAS, which in turn produces cyclic guanosine 
monophosphate-adenosine monophosphate (cGAMP) as second messenger to 
activate STING (118). This pathway plays a critical role against viral invasion like 
HSV infections (218), leading to intracellular release of viral dsDNA. In this setting, 
the IFN-I production acts as a tissue-protective feedback mechanism to induce cell 
death in order to restrain viral replication. Indeed, IL-22 treatment leads to increased 
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accumulation of cytosolic dsDNA in ATG16L1-deficient cells (figure 4-20). The 
potential origin of fragmented dsDNA in the cytosol is either the nucleus or the 
mitochondrion. Release of dsDNA from the nucleus has been described upon 
massive DNA damage induction, e.g. via irradiation or genetic defect in DNA repair 
genes (114). Here, IL-22 treatment increased γH2AX as a DNA damage marker in 
Atg16l1/ATG16L1-knockout cells in vivo and in vitro (figures 4-19 & 4-29). Increased 
proliferation and thus increased speed of DNA replication, making amplifying cells 
prone to replication errors, could explain increase of DNA double strand breaks by IL-
22 treatment. Recently, autophagy has been reported to be crucial in removing 
accumulated DNA fragments (221), which suggest that loss of Atg16l1/ATG16L1 
resulted in increased γH2AX signals. Beyond this, ER stress also affect DNA quality 
as shown in this work (figure 4-31). These findings point towards a possible 
rendezvous between genomic integrity and ER stress resolution and autophagic flux, 
respectively.  
A role for mitochondrial DNA in STING activation needs to be discussed as well. 
Insufficient removal of dysfunctional mitochondria by mitophagy is a critical 
contributor to several neurodegenerative and inflammatory conditions. In the context 
of intestinal inflammation, previous studies described an accumulation of damaged 
mitochondria in Atg16l1-deficiency IECs (154), which makes the possibility of 
relevant leakage of dsDNA to stimulate STING conceivable. To address this, 
ethidium bromide-dependent methods (226) or viral transfection of restriction 
endonucleases (227) to deplete mitochondrial DNA (mtDNA) in ATG16L1-deficient 
vs. proficient cells are necessary. 
5.3 STING drives TNFα induction and necroptosis in 
Atg16l1 deficiency 
In this work, IL-22 induced TNFα (figure 4-25), one of the most central cytokine and 
therapeutic target in intestinal inflammation (228). This induction was dependent on 
STING as Tmem173-/- organoids displayed diminished TNFα induction after IL-22 
treatment (figure 4-24) while IFN-β administration restored Tnf expression (figure 4-
25). One effect of TNFα is the induction of cellular death in inflammatory and 
neoplastic settings (228). While apoptosis was firstly described as the main cell death 
mode and implicated as critical contributor to several inflammatory conditions, 
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growing evidence point towards a more subtle regulation and differentiation of cell 
death involving other modes like necroptosis and their implications for inflammatory 
diseases (229). Necroptosis, “programmed necrosis” of cells, is characterised by 
receptor-mediated signalling, leading to leakage and rupture of the cellular 
membrane and reminiscing a necrotic process. Receptor interacting protein kinase 1 
and 3 (RIPK1, RIPK3) and mixed lineage kinase domain-like (MLKL) are the 
canonical regulators of necroptosis:  
RIPK1 is a serine/threonine kinase which associates to transmembrane death 
receptor complexes including tumour necrosis factor receptor 1 (TNFR1) (230), Fas-
associated protein with death domain (FADD) (231) and tumour necrosis factor 
receptor type 1-associated DEATH domain protein (TRADD) (230) and 
phosphorylates downstream RIPK3 to assemble the so-called necrosome to achieve 
necroptosis induction by TNFα (232). Deficiency of Ripk1 in mice is lethal, whereas 
transgenic mice carrying a Ripk1 D138N variant leading to diminished activity of the 
kinase domain (“kinase dead Ripk1”) were viable and protected from TNFα- and 
poly(I:C)-induced necroptosis in vitro and in vivo (168). In contrast, Ripk3 deficiency 
prevents necroptosis associated cellular and embryonic death in mice deficient for 
FADD (233), FLIP (234) or caspase 8 (235). MLKL, the downstream master regulator 
of necroptosis, works as the indispensable downstream target of the necrosome to 
form cellular pore complexes, which permeabilise the cell after translocation to the 
cellular membrane (236, 237). Dysregulated necroptosis is an important driver of 
epithelial cell death in the gut and -as such- is an emerging pathophysiological 
principle of chronic inflammatory states including human IBD (238-240). However, 
Tnf deletion in mice did not lead to complete resolution of the necroptotic phenotype 
in FADD-deficient animals, particularly in the small intestinal epithelium (240). Thus, 
additional co-stimulatory pathways besides presence of TNFα are necessary for 
necroptosis induction. Interestingly, in macrophages type I interferons are critical for 
induction of RIPK1/RIPK3-dependent necroptosis after bacterial infection (241). In 
this work, treatment of Ripk3-deficient or Ripk1D138N organoids with IL-22 and 
bafilomycin led to unaltered cell death induction versus wild-type controls but 
significantly reduced cell death induction in Mlkl knockout organoids (figure 4-26). 
Tmem173gt organoids were protected from IL-22 and bafilomycin induced cell death 
(figure 4-27). Thus, the IL-22-dependent STING/IFN-I/TNFα loop induces 
RIPK1/RIPK3-independent necroptosis in the context of impaired autophagy. To 
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prove that necroptosis induction in this scenario is dependent on TNFα, 
administration of neutralising anti-TNFα antibodies to IL-22-treated Atg16l1-deficient 
organoids is required. The expected outcome would be cell death prevention by 
TNFα neutralisation. Based on these findings, excessive cell death in the ileal 
intestinal crypts in Atg16l1ΔIEC mice by IL-22 treatment is presumably necroptosis, 
while the absolute proof, e.g. by rescue using necroptosis inhibitors in vivo or 
generation of Atg16l1ΔIEC/MlklΔIEC mice, is still pending.  
It is conceivable that a switch to excessive IFN-I and TNFα induction and subsequent 
programmed cell death may be protective in viral infections, conditions in which 
autophagy and resolution of ER stress are often impaired (242-244). These results 
therefore add to recent findings about the role of autophagy proteins acting as critical 
switches for cellular death modalities (245). Most significantly, the role of Atg16l1 in 
preventing epithelial necroptosis was confirmed in the context of intestinal viral 
infections and graft versus host disease (GvHD) very recently using similar 
biomedical approaches like studying Atg16l1ΔIEC mice and organoids (94). In detail, 
mice with IEC-specific Atg16l1 deletion succumbed to allogenic hematopoietic stem 
cell transplant as well as to DSS colitis after murine norovirus (an ssRNA virus) 
infection (94). This goes along with Paneth cell loss and TNFα-dependent cell death, 
which was rescued with neutralising anti-TNFα antibodies (94). The viability of 
organoids was rescued by necrostatin-1 or knockdown of Ripk3 and Mlkl in Atg16l1 
deficiency while administration of the pan-caspase inhibitor Z-VAD-FMK skewed 
cellular fate towards cell death, indicating that necroptosis is the critical cell death 
mode in these scenarios (94). Mitochondrial dysfunction in autophagy defective cells 
are assumed to be causative for necroptotic death, adding to the theory that Atg16l1 
governs mitochondrial quality by mitophagy in order to prevent mitochondria 
associated cellular damage, e.g. through ROS production (154). Other programmed 
cellular death modes include pyroptosis (246) (inflammasome/caspase 1-mediated 
cell death), ferroptosis (247) (iron-dependent cell death, characterised by the 
accumulation of lipid peroxides), paraptosis (248) (insulin-like growth factor 1 
receptor (IGF-1R)-inducible cell death) and parthanatos (249) (PAR-mediated cell 
death) were not addressed in this work. However, their role in intestinal inflammation 
is enigmatic and therefore would be interesting to study. In particular, inflammasome 
activation and associated cell death has been proposed to be dependent on 
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autophagy (250), however robust evidence towards the role of IBD risk genes like 
ATG16L1 on pyroptosis in IEC are still lacking.  
 
Figure 5-1: Proposed model based on this work 
(a) Immune cell-derived IL-22 activates a regenerative program in wild type IEC. The 
cGAS/STING axis is addressed as well; however, ATG16L1 and XBP1 are protectively 
controlling excessive downstream signalling. (b) Genetic disruption of autophagy or ER 
stress in the intestinal epithelium as in Atg16l1ΔIEC and Atg16l1ΔIEC /Xbp1ΔIEC mice disinhibited 
IL-22-dependent IFN-I induction, which synergistically with IL-22 promote TNFα production. 
This ultimately leads to MLKL-dependent necroptosis, loss of barrier integrity and 
subsequent widespread inflammation.  
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In sum, Atg16l1 controls IL-22-dependent STING signalling to prevent TNFα-induced 
epithelial necroptosis.  
5.4 In the end: New insights into IBD biology or just 
another mouse study?  
In this thesis work, most of the experiments shown were in vivo studies in mice or ex 
vivo investigations conducted in murine intestinal organoids. The findings were 
consistent in the chosen models and suggestive for the transferability into IBD, 
however I did not show studies on primary human (inflamed) material like biopsies or 
organoids in this work. Hence, I will discuss the relevance of this work for human IBD 
in the following. 
The availability of organoids cultures provides a new tool for in vitro research of 
epithelial biology with hallmarks of in vivo tissue (105). Indeed, the feasibility of long-
term culture and storage of organoids reduced the number of sacrificed mice for 
tissue collection purposes. Despite the relatively high costs for organoid cultures at 
the current stage, this will help performing more sustainable science. Another 
advantage is the elegant translation into human IBD settings, as organoids can be 
derived from human samples (like endoscopic biopsies or surgical specimens) (108) 
to study human biology in general or personalised disease signatures in particular. 
However, despite the similarities to the in vivo tissues, organoids are still highly 
artificial systems depending on extrinsic stimuli and growth factors. The culture lacks 
the interplay with luminal microflora and basolateral crosstalk with lamina propria 
cells like immune cells, fibroblasts/fibrocytes and neuronal cells. Co-cultures with 
different cellular types may provide scenarios closer to the in vivo situation but, 
however, will not replace the scientific proof for the in vivo biology. Due to ethical 
aspects, this can only be pursued by animal experiments, e.g. using genetically 
modified mice. 
In this work, the in vivo experiments delivered settings of intestinal inflammation, by 
either genotype-driven spontaneous ileal inflammation (Atg16l1ΔIEC/Xbp1ΔIEC) 
reminiscing CD biology (figure 4-31) or experimental enterocolitis using DSS in 
drinking water (figure 4-28). DSS is a commonly used agent for induction of colitis in 
rodent models (251), which is not absorbed by mucosa. Hence, concentration 
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gradient of DSS along the gastrointestinal tract were found (252), which explains the 
(distal) colon as the major affected site of inflammation, reminiscing UC disease 
pattern. Though, the small intestine has been shown to be more subtly but 
significantly affected by DSS (252). Hence, the purpose of the induction of DSS 
enterocolitis was to enhance disease burden rather than to specifically provoke 
inflammation in the small intestine. Still, DSS models are very artificial and only 
partially reflect human IBD. 
Genetic knockout of disease-related genes is a commonly used strategy to 
approximate human diseases in animal models. In this work, I used conditional 
knockouts to study the role of IBD risk genes in the intestinal epithelium. Using the 
Cre-Lox recombination (253), an essential exon of the gene of interest is removed, 
resulting in loss of the full protein. Here, the villin promotor was chosen to target the 
intestinal epithelium as IECs highly express villin (254). However, renal tube cells 
display villin expression as well (254). This needs to be considered as potential off-
target effect for in vivo studies in this system. To investigate whether the human risk 
variant ATG16L1T300A is responsible for the same phenotype as Atg16l1 deletion in 
mice or not, mice with the CD-associated T300A variant knock-in were generated 
(153). Indeed, these mice displayed a similar phenotype with distorted Paneth cell 
morphology and function in comparison to Atg16l1ΔIEC, which is explained by 
caspase-3-dependent degradation of mutated ATG16L1 (204). Similarly, Xbp1 
depletion in mice approximate the rare IBD risk polymorphisms of XBP1 (e.g. 
rs35873774) which result in hypomorphic XBP1 function (93). 
The deleterious role of IL-22 in the context of defective autophagy and ER stress 
needs to be shown in human samples, e.g. in patient biopsy-derived organoids. 
Stratification of these ileal or colonic organoids for ATG16L1 and XBP1 genotype 
could provide optimal settings for studying IL-22-dependent responses. The potential 
drug IL-22Fc/UTTR1147A needs to be tested for pharmacokinetics/-dynamics and 
potential off-target effects in humans. Furthermore, application of UTTR1147A in 
comparison to recombinant murine IL-22 in the used animal models of this work 
would be interesting. If these results can confirm the murine findings of IL-22 
signalling, genotyping for IBD risk genes will be a prediction tool for response to IL-
22Fc/UTTR1147A. 
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Overall, this study allows new insights in to the biology of intestinal inflammation in 
mice, with a high degree of transferability into chronic inflammation in humans as in 
IBD. Indeed, our working group demonstrated high concordant correlations of IL22, 
TNF, MLKL and ISG mRNA expression and inverse correlation to positive therapy 
response in sigmoid biopsies from IBD patients (cite Paper). Still, more studies are 
necessary to confirm the definite role of the proposed mechanisms in IBD patients.  
5.5 Future prospects 
In this study, I put forward a model whereby under conditions of intestinal injury, 
genetic disease susceptibility in the integrated autophagy/UPR pathway turns a 
regenerative IL-22-dependent response into a vicious circle of tissue damage and 
inflammation. The experiments shown raise another plethora of yet unsolved 
questions towards the biology of this link. As mentioned before, the creation of 
Atg16l1ΔIEC/Tmem173ΔIEC, Atg16l1ΔIEC/IfnarΔIEC and Atg16l1ΔIEC/MlklΔIEC mice are 
useful to ultimately prove the proposed link between autophagy and STING/ISG-
dependent necroptosis induction in synergy with IL-22.  
In colorectal cancer patients, the ATG16L1T300A variants is associated with increased 
IFN-I signalling and improved survival (216). On the contrary, the IL-22 is a strong 
driver of carcinogenesis (78). Thus, the role of IL-22 in Atg16l1 deficiency on 
inflammatory-driven carcinogenesis would be interesting to study. Intraperitoneal 
administration is not feasible due to the duration of classical carcinogenesis models 
using azoxymethane (AOM) and DSS (255) and the high costs of recombinant 
murine IL-22. Therefore, the Atg16l1ΔIEC mice need to be crossed with either IL-22 
overexpressing transgenic mice or mice deficient for Il22bp (resulting in disinhibited 
IL-22 signalling) before undergoing AOM/DSS regimens.  
As described above, immunogenic cell death modes like necroptosis and pyroptosis 
play important roles in IBD pathophysiology. After providing evidence of autophagy 
controlled necroptosis in the intestinal epithelium, the role of autophagy in 
inflammasome activation in intestinal epithelial cells needs to be addressed in further 
studies. For instance, the IBD risk gene LRRK2 encodes for the autophagy-related 
protein LRRK2 interacting with NLRC4 (256). STING and AIM2, a sensor for cytosolic 
dsDNA involved in inflammasome formation, are reciprocally regulated (257). Thus, 
we will study the role of different inflammasome proteins in Atg16l1 deficient IEC.  
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Another point of interest is the hitherto underestimated role of DNA damage in the 
pathogenesis of intestinal inflammation. In a genetic mouse model of massive 
accumulation of DNA damage in the intestinal epithelium and subsequent 
upregulation of the STING/IFN-I axis, Rnaseh2b controls excessive inflammation by 
modulating STING signalling in a p53-dependent fashion in preliminary results. 
Interestingly, increased intestinal inflammation level was associated with p53-
dependent tumour suppression in cancerogenesis models, whereas additional 
depletion of p53 in the intestinal epithelium resulted in spontaneous tumour 
formation. In this context, Atg16l1 and Xbp1 control p53-related cellular responses in 
ongoing experiments in Atg16l1ΔIEC/Rnaseh2bΔIEC and Xbp1ΔIEC/Rnaseh2bΔIEC mice 
and organoids. These finding give rise to several follow-up experiments addressing 
the molecular mechanism of ATG16L1/XBP1/STING interactions in inflammatory and 
neoplastic conditions.  
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6 Summary 
Inflammatory bowel diseases (IBD) are playing a more and more important 
socioeconomic role due to increasing incidences. However, the detailed 
pathophysiology is not fully understood, yet. This is reflected by the yet unsatisfactory 
treatment efficiency of even the most modern drugs under development. Genetic 
factors, environmental triggers, lifestyle and microbial signals are interactively 
contributing to the development of IBD.  
Coding variants of the IBD risk genes ATG16L1 and XBP1 have been associated 
with defective autophagy, deregulation of endoplasmic reticulum (ER) function and 
impaired pathogen clearance. IL-22 is a barrier protective cytokine by inducing 
regeneration and antimicrobial responses in the intestinal mucosa.  
Here, we show that XBP1 and ATG16L1 critically orchestrates beneficial IL-22 
signalling in intestinal epithelium. IL-22 stimulation physiologically leads to transient 
ER stress, intracellular release of dsDNA and subsequent activation of the cGAS-
STING pathway. Loss of ATG16L1 exacerbates IL-22-induced ER stress and 
augments STING-dependent IFN-I responses in IECs. IFN-I amplifies epithelial TNFα 
production downstream of IL-22 and leads to necroptotic cell death. In vivo, IL-22 
treatment in Atg16l1ΔIEC mono- and Atg16l1ΔIEC/Xbp1ΔIEC double knockout mice 
potentiates endogenous ileal inflammation and causes widespread necroptotic 
epithelial cell death, which can be partially rescued by neutralising the IFN-I signalling 
using anti-IFNAR antibodies. Under conditions of chronic intestinal inflammation and 
with clear genetic “hits” to the autophagic and ER stress machinery like in human 
IBD, however, such a fate of IL-22 signals may crucially contribute to a vicious circle 
of tissue damage and inflammation.  
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7 Zusammenfassung 
Chronisch-entzündliche Darmerkrankungen (CED) spielen auf Grund einer 
steigenden Inzidenz eine zunehmende sozioökonomische Rolle mit einer 
wachsenden Belastung für das Gesundheitssystem. Dennoch ist die 
Pathophysiologie bislang noch nicht vollständig verstanden, was sich in der aktuell 
insgesamt noch unzufrieden-stellenden medikamentösen Therapie widerspiegelt. Zur 
Entwicklung einer CED spielen interaktiv sowohl genetische Faktoren als auch 
Umweltfaktoren, der Lebensstil und mikrobielle Signale eine bedeutende Rolle.  
Verschiedene kodierende Varianten der CED-Risikogene ATG16L1 und XBP1 sind 
assoziiert mit defekter Autophagie, einer Dysregulation der Funktion des 
Endoplasmatischen Retikulums (ER) sowie einer gestörten Abwehr gegen 
Pathogene. Demgegenüber wird das Interleukin (IL)-22 in der intestinalen Mukosa 
als Barriere-schützendes Zytokin, welches die epitheliale Regeneration und die 
antimikrobielle Antwort in der intestinalen Mukosa vermittelt, gebildet.  
In dieser Arbeit wurde gezeigt, dass ATG16L1 und XBP1 kritische Regulatoren 
dieses protektiven IL-22-Signals sind. IL-22-Stimulation führt zu physiologischem, 
transientem ER-Stress, einer intrazellulären Freisetzung von doppelsträngiger 
Desoxyribonukleinsäure und nachfolgender Aktivierung des cGAS-STING-
Signalweges. Eine Depletion von ATG16L1 führt zu einer Exazerbation des IL-22-
induzierten ER-Stress und verstärkt die STING-abhängige Typ-I-Interferon-Antwort in 
intestinalen Epithelzellen. Typ-I-Interferone amplifizieren die IL-22-abhängige 
epitheliale Produktion von Tumornekrosefaktor-α (TNF-α), welche schließlich zu 
nekroptotischem epithelialen Zelltod führt. In vivo potenziert eine IL-22-Behandlung 
von Atg16l1ΔIEC- und Atg16l1ΔIEC/Xbp1ΔIEC-Mäusen deren endogene Inflammation im 
Ileum, welche mit einer massenhaften Nekroptose von intestinalen Epithelzellen 
verbunden ist. Neutralisierung des Typ-I-Interferon-Signals durch einen anti-IFNAR-
Antikörper kann diese Inflammation teilweise eindämmen. Im Kontext von 
chronischen intestinalen Entzündungen und einer klaren genetischen Affektion der 
Autophagie-ER-Stress-Achse wie bei einer CED ist eine solche Effektumkehr des IL-
22-Signals ein potenzieller Faktor, welcher den Teufelskreislauf von Gewebsschäden 
und Inflammation unterhält.  
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8 Appendix 
8.1 Buffers and Media 
Table 7: Table of used buffers  
Devices Composition Company 
10 x TBS 
200 mM Tris (pH 7.6) 
1,37 M NaCl 
- 
10 x TGS buffer 
25 mM Tris (pH 8.3) 
92 mM glycine 
0.1 % SDS 
BioRad (Munich, 
Germany) 
2 x DLB buffer 
20 mM Tris (pH 7.4) 
2 % SDS 
- 
5 x SDS loading dye 
250 mM Tris (pH 6.8) 
10 % SDS 
50 % glycerol 
500 mM DTT 
- 
anode buffer 1 
30 mM Tris 
20 % methanol 
- 
anode buffer 2 
300 mM Tris 
20 % methanol 
- 
cathode buffer 
25 mM Tris 
40 mM 6-aminocaproic acid 
20 % methanol 
- 
citrate buffer 11 mM Citric acid (pH 6.0) - 
phosphate-buffered saline 
(PBS) 
1 mM KH2PO4 
155 mM NaCl 
3 mM Na2HPO4-7H2O 
Gibco (Darmstadt, 
Germany) 
separation buffer 
1.5 M Tris (pH 8.8) 
0.4 % SDS 
- 
stacking buffer 
0.5 M Tris (pH 6.8) 
0.4 % SDS 
- 
stripping buffer 
2 % SDS 
62.5 mM Tris (pH 6.8) 
- 
T/TBS 
1 x TBS 
0.1 %Tween20 
- 
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Table 8: Table of used media 
Media Company 
Advanced DMEM/F12 medium Gibco (Darmstadt, Germany) 
CryoStor™ CS10 StemCell Technologies (Cologne, Germany) 
DMEM cell culture medium Gibco (Darmstadt, Germany) 
Hank´s Balanced Salt Solution (HBSS) Gibco (Darmstadt, Germany) 
IntestiCult™ Organoid Growth Medium 
(Mouse) 
StemCell Technologies (Cologne, Germany) 
MEM cell culture medium Gibco (Darmstadt, Germany) 
RPMI cell culture medium Gibco (Darmstadt, Germany) 
8.2 Kits 
Table 9: Table of used kits 
Kit Company 
ApopTag® Plus Peroxidase In Situ 
Apoptosis Detection Kit 
Merck Millipore (Darmstadt, Germany) 
DC™ Protein Assay Bio-Rad (Munich, Germany) 
IL-8 Human ELISA Kit 
ThermoFischer Scientific (Darmstadt, 
Germany) 
Maxima H Minus First Strand cDNA 
Synthesis kit 
ThermoFischer Scientific (Darmstadt, 
Germany) 
HiSeq Reagent Kit v4 (2 x 150 bp) Illumina (San Diego, USA) 
RNeasy kit Qiagen (Hilden, Germany) 
Vectastain Elite ABC Kit Rabbit IgG Vector Labs (Peterborough, United Kingdom) 
8.3 Reagents and chemicals 
Table 10: Table of used reagents and chemicals 
Reagent/chemical Company 
1 % Eosin solution Roth (Karlsruhe, Germany) 
10 % Formalin Sigma Aldrich (Munich, Germany) 
10 x SYBR® Safe DNA gel stain Life Technologies (Darmstadt, Germany) 
30 % Bis-acrylamide (37.5:1) Bio-Rad (Munich, Germany) 
4-(2-hydoxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) 
Sigma Aldrich (Munich, Germany) 
5 x Green GoTaq® Reaction Buffer Promega (Mannheim, Germany) 
6-aminocaproic acid Sigma Aldrich (Munich, Germany) 
agarose Biozym (Hessisch Oldendorf, Germany) 
ammonium persulfate (APS) Sigma Aldrich (Munich, Germany) 
bafilomycin A 
Enzo Life Sciences GmbH  
(Lörrach, Germany) 
blotting grade blocker (non-fat dry milk) Bio-Rad (Munich, Germany) 
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bovine serum albumin (BSA) Roth (Karlsruhe, Germany) 
citric acid Roth (Karlsruhe, Germany) 
deoxynucleotide triphosphates (dNTPs) 
ThermoFischer Scientific  
(Darmstadt, Germany) 
dimethyl sulfoxide (DMSO) Sigma Aldrich (Munich, Germany) 
dithiothreitol (DTT) Sigma Aldrich (Munich, Germany) 
DreamTaq DNA Polymerase 
ThermoFischer Scientific  
(Darmstadt, Germany) 
ECL™ Western Blotting Detection Reagents GE Healthcare (Hamburg, Germany) 
epidermal growth factor (EGF) (recombinant 
human) 
Peprotech (Hamburg, Germany) 
ethanol Roth (Karlsruhe, Germany) 
ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich (Munich, Germany) 
foetal bovine serum (FBS) Merck Millipore (Darmstadt, Germany) 
glycerol Roth (Karlsruhe, Germany) 
hematoxylin solution Th Geyer (Renningen, Germany) 
hydroxyurea Sigma Aldrich (Munich, Germany) 
interferon-β (IFN-β) (recombinant mouse) Peprotech (Hamburg, Germany) 
interleukin-10 (IL-10) (recombinant mouse) Peprotech (Hamburg, Germany) 
interleukin-22 (IL-22) (recombinant mouse) Peprotech (Hamburg, Germany) 
interleukin-22 (IL-22) (recombinant human) Peprotech (Hamburg, Germany) 
interleukin-23 (IL-22) (recombinant mouse) Peprotech (Hamburg, Germany) 
Matrigel BD Biosciences (Heidelberg, Germany) 
methanol Roth (Karlsruhe, Germany) 
N,N,N',N'-tetramethylethylendiamin  
(TEMED) 
Sigma Aldrich (Munich, Germany) 
nuclease-free water Qiagen (Hilden, Germany) 
paraffin 
ThermoFischer Scientific  
(Darmstadt, Germany) 
penicillin/streptomycin (10,000 U/mL) Life Technologies (Darmstadt, Germany) 
Phusion HotStart Flex 2 Master Mix 
New England Biolanbs GmbH  
(Frankfurt a.M., Germany) 
Pierce ECLTM Plus Western Blotting 
Substrate 
ThermoFischer Scientific (Darmstadt, 
Germany) 
propidium iodide (PI) Sigma Aldrich (Munich, Germany) 
protease and phosphatase inhibitor 
ThermoFischer Scientific  
(Darmstadt, Germany) 
proteinase K 
ThermoFischer Scientific  
(Darmstadt, Germany) 
rapamycin (Streptomyces hygroscopicus) Sigma Aldrich (Munich, Germany) 
Roti-Histokitt mounting medium Roth (Karlsruhe, Germany) 
S3I-201 EMD Millipore (Darmstadt, Germany) 
sodium chloride (NaCl) Merck Millipore (Darmstadt, Germany) 
sodium dodecyl sulfate (SDS) Roth (Karlsruhe, Germany) 
SYBR® Select Master Mix Applied Biosystems (Darmstadt, Germany) 
TaqMan Gene Expression Master Applied Biosystems (Darmstadt, Germany) 
Tris Merck Millipore (Darmstadt, Germany) 
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TrypLE Express 
ThermoFischer Scientific  
(Darmstadt, Germany) 
tunicamycin Calbiochem (Darmstadt, Germany) 
Tween 20 Roth (Karlsruhe, Germany) 
xylene 
ThermoFischer Scientific (Darmstadt, 
Germany) 
8.4 Devices 
Table 11: Table of used devices 
Devices Company 
100-1000 μl pipette Eppendorf (Hamburg, Germany) 
10-100 μl pipette Eppendorf (Hamburg, Germany) 
10-200 μl multi-channel pipette Eppendorf (Hamburg, Germany) 
1-10 μl pipette Eppendorf (Hamburg, Germany) 
7900HT Fast Real Time PCR System Applied Biosystems (Darmstadt, Germany) 
agarose gel chamber wide mini sub-cell GT Bio-Rad (Munich, Germany) 
automatic developer machine Curix 60 Agfa (Mortsel, Belgium) 
Axio Imager Z1 ZEISS (Oberkochen, Germany) 
balance PeqLab (Erlangen, Germany) 
cell counter (Cellometer Auto T4 Plus) Heraeus (Hanau, Germany) 
centrifuge Fresco21 Centrifuge Heraeus (Hanau, Germany) 
centrifuge Megafuge 16 Bio-Rad (Munich, Germany) 
ChemiDoc XRS Biometra (Göttingen, Germany) 
electrophoresis chamber Multigel G44 Tecan (Männedorf, Switzerland) 
ELISA plate shaker 
ThermoFischer Scientific (Darmstadt, 
Germany) 
ELISA washer Columbus plus BD Biosciences (Heidelberg, Germany) 
embedding station STP120 Applied Biosystems (Darmstadt, Germany) 
FACSCaliburTM BD Biosciences (Heidelberg, Germany) 
GeneAmp PCR System 9700 Sartorius (Göttingen, Germany) 
incubator Tecan (Männedorf, Switzerland) 
magnetic stirring plate Severin (Sundern, Germany) 
microplate reader Infinite M200 Pro Illumina (San Diego, USA) 
microwave PeqLab (Erlangen, Germany) 
HiSeq 3000 sequencer Illumina (San Diego, USA) 
NanoDrop spectrometer ND1000 Biometra (Göttingen, Germany) 
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power Supply PP 3000 Bandelin (Berlin, Germany) 
RM2255 microtome Heraeus (Hanau, Germany) 
sonificator Sonopuls Eppendorf (Hamburg, Germany) 
sterile bench Herasafe KS12 Bio-Rad (Munich, Germany) 
Thermomixer compact ZEISS (Oberkochen, Germany) 
TransBlot Turbo Transfer System 
Stuart Scientific (Chelmsford, United 
Kingdom) 
tube rotator SRT6 GFL (Burgwedel, Germany) 
Vortex Genie 2 Scientific Industries (New York, USA) 
Water Bath 1013 GFL (Burgwedel, Germany 
8.5 Consumables 
Table 12: Table of used consumables 
Consumables Company 
0.5 ml/1.5 ml/2.0 ml tubes Sarstedt (Nümbrecht, Germany) 
1.5 ml/2.0 ml safe seal tubes Sarstedt (Nümbrecht, Germany) 
10 ml syringe BD Biosciences (Heidelberg, Germany) 
1-10 μl/10-100 μl/100-1000 μl pipette (filter) tips Sarstedt (Nümbrecht, Germany) 
15 cm/10 ml petri dish Sarstedt (Nümbrecht, Germany) 
15 ml/50 ml tubes Sarstedt (Nümbrecht, Germany) 
18G/20G/26G needles BD Biosciences (Heidelberg, Germany) 
1 ml syringe BD Biosciences (Heidelberg, Germany) 
384-well plates Life Technologies (Darmstadt, Germany) 
100 μm cell strainer BD Biosciences (Heidelberg, Germany) 
5 ml/10 ml/25 ml pipettes Sarstedt (Nümbrecht, Germany) 
6-well/12-well/24-well/96-well plate (flat bottom) Sarstedt (Nümbrecht, Germany) 
Amersham Hyperfilm ECL GE Healthcare (Hamburg, Germany) 
cell scraper Sarstedt (Nümbrecht, Germany) 
coversplips (24x50mm) Geyer (Renningen, Germany) 
FACS tubes Greiner (Frickenhausen, Germany) 
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IgA    immunoglobulin A 
IGF-1R   insulin-like growth factor 1 receptor 
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IL    interleukin 
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mTOR    mechanistic Target of Rapamycin 
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NCR    natural cytotoxicity receptor 
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NOD2    nucleotide-binding oligomerization domain-containing protein 2 
NOX1    NADPH oxidase 1 
ORMDL3   ORM1-like protein 3 
p40    interleukin-12 subunit p40 
p53    tumor protein 53 
PAGE    polyacrylamide gel electrophoresis 
PAMP    pathogen-associated molecular pattern 
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PAR    poly(ADP-ribose) 
PBC    primary biliary cirrhosis 
PBS    phosphate-buffered saline 
PCR    polymerase 
PI    propidium iodide 
PKR    protein kinase R 
poly(I:C)   polyinosinic:polycytidylic acid 
PSC    primary sclerosing cholangitis 
PVDF    polyvinylidene fluoride 
qPCR    quantitative (real time) PCR 
REG3B/G   regenerating islet-derived 3 β/γ 
RFP    red fluorescent protein 
RIG-I    retinoic acid-inducible gene I 
RIPK    receptor-interacting serine/threonine-protein kinase 1 
RNA    ribonucleic acid 
RNASEH2B   ribonuclease H2, subunit B 
RNAseq   RNA sequencing 
ROS    reactive oxygen species 
RPMI buffer   Roswell Park Memorial Institute buffer 
S100A8/9   S100 calcium-binding protein A8/9 
SDS    sodium dodecyl sulphate 
SLE    systemic lupus erythematosus 
SMAD7   mothers against decapentaplegic homologous 7 
SNP    single nucleotide polymorphism 
ssRNA    single stranded RNA 
STAT    signal transducer and activator of transcription 
STING    stimulator of interferon genes 
STRING   Search Tool for the Retrieval of Interacting Genes/Proteins 
TAC    transit amplifying cells 
TBK1    TANK-binding kinase 1 
TBS    Tris-buffered saline 
TCF-4    transcription factor 4 
TFBS    transcription factor binding site 
TGF-β    transforming growth factor beta 
TGS    Tris/glycine/SDS 
Th cells   T helper cells 
TLR    Toll-like receptor 
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TM    tunicamycin 
TNFα    tumor necrosis factor alpha 
TNFR1   TNF receptor 1 
TRADD   TNF receptor type 1-associated death domain protein 
TRIF    TIR-domain-containing adapter-inducing interferon-β 
TRIM    tripartite motif family 
T/TBS    TBS supplemented with Tween 20 (1%) 
TUNEL   terminal deoxynucleotidyl transferase dUTP nick end labeling 
TYK2    tyrosine kinase 2 
UC    ulcerative colitis 
UPR    unfolded protein response 
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WNT    Wingless-type MMTV integration site family 
XBP1    X-box binding protein 1 
XIAP    X-linked inhibitor of apoptosis protein 
YAP    Yes-associated protein 
ZO-1    zonula occludens-1 
Z-VAD-FMK carbobenzoxy-valyl-alanyl-aspartyl-(O-methyl)- 
fluoromethylketone 
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